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 The Corynebacterium – Mycobacterium – Nocardia family (CMN 
family) are a subset group of actinomycetes which are characterized as 
acid-fast, Gram-positive species. Many members of the CMN family are 
causative agents of human disease with M. tuberculosis, M. leprae, C. 
diptheria, and N. asteroides historically being exceptionally hard to treat 
pathogens. One of the reasons the CMN family are resistant to treatment 
is also the defining trait of the family, which is the presence of an outer 
membrane with a unique composition of peptidoglycan crosslinked to an 
arabinogalactan matrix which is further crosslinked to mycolic acids 
forming an effective outer barrier.  
 This peptidoglycan – arabinogalactan – mycolic acid barrier forms 
the inner leaflet of the outer membrane, with loosely associated mycolic 
acids esterified to disaccharide trehalose sugars forming the outer leaflet 
of the outer membrane. Both of these structural features together form the 
‘myco-membrane’ which is even further complicated by the presence of an 
outer capsular layer comprised mainly of extended sugar polymers and 
proteins which are thought to be involved in regulating the hosts’ immune 
response. 
 The proper biosynthesis of the myco-membrane is essential for the 
viability of CMN family pathogens, and the unique physiology of the myco-
membrane has made it a primary target for pharmacological therapeutics. 
In addition to targeting peptidoglycan, the treatment of CMN family 
pathogens can also include the disruption of arabinogalactan 
polymerization and the synthesis of fatty acids used in the construction of 
the more complicated mycolic acids.  
 Mycolic acids are long-chain saturated fatty acids unique to the 
CMN family and are found exclusively in the outer myco-membrane. 
Significant efforts have gone into documenting the biosynthetic pathway of 
mycolic acid, where it was revealed that the catalytic steps necessary to 
form these long-chain fatty acids are completed inside the bacterial cell. 
ix 
 
This raised the question of how these mycolic acids cross the cell 
membrane in order to be incorporated in the outer membrane. In M. 
tuberculosis it was shown that mycolic acids could not translocate to the 
outer leaflet of the inner membrane without the function of the essential 
membrane transporter MmpL3. The role of MmpL3 as a mycolic acid 
transporter has since been validated, and MmpL3 has been pursued as a 
novel pharmacological target. Despite the significance of this discovery, 
the exact mechanism by which MmpL3 transports mycolic acids across 
the cell membrane had not yet been described.   
The focus of this thesis is on the mechanistic function of the 
essential mycolic acid membrane transporters CmpL1 from C. glutamicum 
and MmpL3 from M. tuberculosis, their interactions with inhibitors, and the 
discovery of novel protein-MmpL3 interactions. To begin our study, we 
undertook the purification of MmpL3 from M. tuberculosis and CmpL1 from 
C. glutamicum, and reconstituted them into functional proteoliposomes. 
Our results from this experiment demonstrate that the mycolic acid 
transporters facilitate H+ flux across the membrane which is stimulated in 
the presence of a substrate analog. 
As MmpL3 is a significant therapeutic target, several MmpL3 
inhibitors have been developed and are in clinical trials. Therefore, we 
next moved to determine whether these inhibitors directly interact with 
MmpL3, and if they carry out their function through the inhibition of the 
observed H+ transport. We utilized a Surface Plasmon Resonance (SPR) 
assay to successfully determine the direct interaction of a variety of 
pharmacophores, and we report the kinetic rates of the interactions. 
Continuing the study of mycolic acid transport inhibition, we pursued a set 
of novel indole-2-carboxamide (IC) compounds which had both direct 
interaction and good activity in minimum inhibitory concentration (MIC) 
assays against M. tuberculosis MmpL3 and C. glutamicum CmpL1. We 
utilized these IC inhibitors in the proteoliposome assays and report our 
x 
 
results that the inhibition of mycolic acid transport is due to the inhibition of 
H+ flux across the membrane. 
MmpL3 carries out the essential function of transporting mycolic 
acids across the plasma membrane of the bacterial cell. For proper cell 
wall biogenesis, the timing and incorporation of mycolic acid into the 
nascent cell wall would need to be coordinated with other biosynthetic 
machinery. We hypothesized that there would need to be other proteins 
associated to MmpL3. To test this hypothesis, we identified potential 
protein interactions via a bacterial two-hybrid screen of the entire Mtb 
proteome with MmpL3. Potential interacting proteins were independently 
purified and assayed for direct interaction with MmpL3 using SPR, and we 
report our results confirming high affinity interactions with several proteins. 
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CHAPTER 1: INTRODUCTION 
This chapter introduces the Corynebacterium-Mycobacterium-Nocardia 
(CMN) family of human pathogens, and the difficulty of treating infections 
caused by this family in the context of their unique outer membrane when 
compared to other bacterial membranes.  
 
1.1 – The Corynebacterium-Mycobacterium-Nocardia 
Family 
The actinomycetes are a large and diverse phylum of Gram-
positive prokaryote species which can be either aquatic or terrestrial1. 
Contained in this phylum are species which stain acid-fast due to the 
presence of a complex outer membrane comprised of peptidoglycan – 
arabinogalactan – and mycolic acids2. Members which contain this 
conserved unique structural feature are the Corynebacterium, 
Mycobacterium, and Nocardia species and thus are grouped into the 
Corynebacterium-Mycobacterium-Nocardia (CMN) Family3. 
Mycobacterium tuberculosis (Mtb) is the leading source for 
infectious disease worldwide, with an estimated one-third of the global 
population carrying the tuberculosis causing pathogen4.  M. tuberculosis is 
an aerobic rod-shaped and acid-fast Gram-positive bacterium, and 
infection with Mtb predominately occurs due to inhalation of aerosolized 
droplets in the air which have been expelled from an afflicted patient 5. 
Although infection can occur in other bodily tissues, most Mtb infections 
occur in the lungs are diagnosed with the characteristic presentation of 
granuloma formation6,7. Granuloma formation begins during infection, as 
Mtb bacilli which are phagocytosed by macrophages prevent lysosomal 
fusion to the encapsulating phagosome8-10; proliferating inside the 
phagosome until escaping into the macrophage10. Once free inside the 
macrophage Mtb secretes tuberculosis necrotizing toxin (TNT) which 
induces necroptosis by way of NAD+ hydrolysis, effecting the bacilli’s 
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escape11. During this process, uninfected host macrophages and dendritic 
cells surround the infected macrophages and are stimulated by CD4 T-
helper cells 12 creating a ball around the infecting bacteria which forms the 
resultant granuloma 13. In the majority of cases granuloma formation is 
stable and patients can be asymptomatic for decades; for reasons still not 
fully understood, approximately ten percent of these ‘latent’ TB infections 
become active TB disease and present with the full suite of symptoms 
14,15. Approximately 50% of active MDR-TB cases result in patient 
mortality4.  
M. tuberculosis is the most well-known and studied species from 
the CMN family, however there are many significant human pathogens 
belonging to this group. Mycobacterium leprae is the causative agent for 
leprosy, a slow-growing infection of the skin, nerves, eyes, and extremities 
16. Nervous system infection of M. leprae results in the complete loss of 
sensation of the affected nerves, which further leads to extremity loss due 
to unfelt injuries and infections17. M. leprae is among the slowest growing 
pathogens in the CMN family, with symptoms commonly not presenting 
until a year post infection, and some patients not developing symptoms for 
twenty or more years 18. Mycobacterium kansasii and Mycobacterium 
abscessus are both considered Non-Tubercular Mycobacterial (NTM) 
infections, can establish infection in any bodily organ, and are extensively 
resistant to antibiotics and disinfectants19,20. These traits have led to an 
increase in nosocomial infections in immunocompromised patients, and 
currently NTM are considered an emerging threat 21. 
Nocardia asteroides (among other Nocardia species) afflicts the 
host with nocardiosis, an infection typically affecting the lungs and skin, 
however once the infection is established and without proper care, the 
infection disseminates and can spread to the brain and spinal cord 22. 
Once the neural tissue becomes infected, brain abscesses form and 
patient mortality rises to approximately 38% which additionally increases 
to over 60% in immunocompromised patients23,24. 
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Corynebacterium diphtheria is the disease-causing agent of 
diphtheria, an infection that begins in the throat before going on to induce 
myocarditis, nerve paralysis, and excessive bleeding through the 
production of diphtheria toxin in infected patients 25. Diphtheria, even with 
proper medical care has a high morbidity rate of up to 17% , prompting the 
development of a diphtheria vaccine26 which is highly effective against C. 
diphtheria; however, recently Corynebacterium ulcerans has been shown 
to also produce diphtheria toxin in human infections making it another 
reservoir of human disease3,27. The disease burden created by members 
of the CMN family is extreme28, with most requiring twelve month or longer 
combination therapy to clear the infections, to variable success rates29.  
 
1.2 – The CMN Family Cell Envelope is Unique Among 
Bacteria. 
 
The bacterial cell wall is a defining phenotype of different species 
and functions as the first line of defense against environmental 
fluctuations and antibacterial compounds30. The principle taxonomic 
technique for the identification of bacterial species is the Gram stain 31, in 
which the bacterial population under test is separated into two groups 
based on the ability to retain different dyes. In a Gram-positive organism 
(Figure 1), there is a thick layer (20-80 nm)32 of peptidoglycan which 
readily retains the crystal violet principle dye of the Gram stain, whereas in 
a Gram-negative organism this crystal violet is not retained in the much 
thinner peptidoglycan (4-8 nm)30,33 and is subsequently counterstained 
with a secondary dye. Peptidoglycan (PG) is a barrier formed on the outer 
surface of the cell consisting of sugars and short peptides. The main 
component of the PG cell wall is the long-chain alternating polymer of N-
acetylglucosamine and N-acetylmuramic acid which runs along the long 
circumference of the cell34. These long sugar chains are then cross-linked 
via a transpeptidase reaction by short well-defined peptides 35, and once 
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the NAG-NAM polymer strands have been crosslinked this imparts 
strength and rigidity as multiple layers are stacked 36. The second major 
component of the Gram-positive cell wall are the teichoic acids, which are 
polymer chains of either polyribitol phosphate or polyglycerol phosphate37 
and can be found anchored to either the N-acetylmuramic acid residues of 
the PG layer or to an integral plasma membrane lipid38. These teichoic 
acids impart significant negative charge to the cell wall and thus bind 





Figure 1 – Representation of a Gram-positive Cell Wall 
Cartoon schematic of a Gram-positive bacterial cell wall. A thick 
peptidoglycan layer (Blue / Orange bricks) are crosslinked via a 
transpeptidase reaction (Black links) to impart rigidity. Teichoic acids 
(Green) and lipoteichoic acids (Yellow) provide structural support and 











The Gram-negative cell wall (Figure 2) possesses a similar plasma 
membrane which is reinforced by a PG layer; however it is not as 
substantial with a thickness of approximately 10% of a Gram-positive 
species33. Instead the defining trait of a Gram-negative bacteria is the 
presence of an outer membrane which fully encapsulates the cell and 
partitions off a functional periplasm40. The Gram-negative outer membrane 
is asymmetric, with the inner leaflet consisting of phospholipids and the 
outer leaflet of the outer membrane composed of lipopolysaccharide 
(LPS)41. Proteins present in the outer membrane are predominately porins 
to facilitate nutrient uptake42,43, or beta-barrel channels which function as 
components of the Resistance-Nodulation-Division (RND) class of 
tripartite efflux pump assemblies44,45. RND efflux pumps are tripartite 
complexes consisting of: the RND substrate:H+ antiporter located 
spanning the plasma membrane, an outer membrane channel through 
which substrates are pumped out of the cell, and a membrane fusion 
protein which connects the RND pump to the outer membrane pore46. This 
tripartite assembly is unique to Gram-negative bacteria and functionally 
allows the active efflux of toxic compounds in the periplasm back out of 
the cell47. The combined effect of the outer membrane permeability barrier 
with the active efflux of drugs makes the Gram-negative bacteria much 
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Figure 2 – Representation of a Gram-negative Cell Wall 
A cartoon representation of a typical Gram-negative cell wall. A thinner 
layer of peptidoglycan (Blue / Orange bricks) is found as compared to 
Gram-positive bacteria. An asymmetric outer membrane encapsulates the 
cell, with the inner leaflet formed of phospholipids and the outer leaflet 
formed of lipopolysaccharide (Grey strands). Also illustrated is an 
assembled RND tripartite assembly, the RND pump (Gold) is connected to 
the Outer membrane Channel (Green) via a Membrane Fusion Protein 
(Red). 
 
The CMN family are classified as acid-fast Gram-positive species, 
however they are unique in that they have an asymmetric outer membrane 
surrounding their peptidoglycan cell wall50. This structural feature, which is 
visualized under microscopy as a thick, waxy outer myco-membrane51 is 
what characterizes these bacteria as some of the most difficult to treat 
pathogens. Due to its extremely hydrophobic nature it is thus impermeable 
to polar and ionic solutes, and has a significantly lower hit rate for the 
discovery of novel antibiotic compounds45. The myco-membrane origin 
starts at the cell membrane, covalently coupled to a layer of peptidoglycan 
which differs in significant ways from traditional Gram-positive pathogens52 
(Figure 3). PG from M. tuberculosis consists of alternating units N-
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acetylmuramic acid and N-glycolylmuramic acid53,54, and the presence of 
this glycolyl modification has been shown to increase resistance to 
lysozyme activity55. The peptide crosslinking in mycobacterial PG is also 
significantly more robust, with 20-30% 56 more observed crosslinks when 
compared to E. coli 57. On the PG layer an alternating matrix of arabinose-
galactose (AG) units are crosslinked58 by the activity of the LytR-CpsA-Psr 
(LCP) family of proteins. In C. glutamicum LcpA and LcpB carry out this 
reaction with redundant activity, and the double knockdown presenting 
severe cell wall defects 59. The M. tuberculosis analogs CpsA1 and CpsA2 
were also shown to have overlapping activity, where double deletions 
were not able to generate viable cells 50, and the phosphotransferase Lcp1 





Figure 3 – Representation of a CMN Family Cell Envelope 
Cartoon representation of a typical CMN family cell envelope. A periplasm 
is found exterior to the plasma membrane with the cell wall core tethered 
to plasma membrane by lipoarabinomannans (Green barrels), and 
consists of peptidoglycan (PG – Blue / Orange bricks) linked to 
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arabinogalactan (AG – Purple / Cyan hexagons) and covalently attached 
mycolic acids (Yellow lines). This forms the inner leaflet of the outer myco-
membrane, with the outer leaflet formed of loosely associated mycolic 
acids (Green hexagons with Red lines). The external capsular layer 





To the distal arabinogalactan (AG) layer mycolic acids, long-chain 
saturated lipids, are esterified with the hydrophobic tails extending away 
from the cell forming the inner leaflet of the outer myco-membrane61. An 
asymmetric outer leaflet is composed of free trehalose mycolates, the 
main component being trehalose dimycolate (TDM)62 (Figure 4). TDM is 
formed from two molecules of trehalose monomycolate (TMM) by 
extracellular Antigen 85 (Ag85) enzymes catalyzing the transfer of one 
mycolic acid from one TMM onto the trehalose of a second TMM releasing 
a free trehalose disaccharide63,64. TMM, though a smaller component of 
the outer membranes outer leaflet, is the major building block of the outer 
myco-membrane; it is the source of the mycolic acids which are esterified 
to the arabinogalactan matrix as well as being consumed to form TDM in 
the outer leaflet of the outer membrane62. Curiously, this extremely large 
hydrophobic lipid is synthesized inside the cell and must then be 
transported across the cell membrane so it can be utilized in cell wall 
synthesis65.  
 
9 | P a g e  
 
 
Figure 4 – Structures of Mycobacterial Mycolic Acids 
A) Structure of Trehalose Mono-Mycolate (TMM) with indicated α- branch 
and mero-chain of the mature mycolate.  B) Structure of Trehalose 
Dimycolate (TDM), with two mycolates coupled to one trehalose sugar.  
 
Located distal to the outer leaflet of the outer myco-membrane is 
the loosely bound ‘capsular layer’ which is comprised mostly of sugars 
and proteins with the main components being α-D-glucan and 
arabinomannan66,67. This sugary capsule layer has been implicated in the 
regulation of the host immune response to infection, with the 
lipoarabinomannan being proposed as an immune system evasion 
mechanism via its ability to prevent phagolysosomal fusion 8. The outer 
leaflet and capsular layer also contains many complex lipid species, 
phthiocerol dimycocerosates (PDIM), lipooligosaccharides (LOS), and 
phenolic glycolipids (PGL) which have all been shown to have roles in 
transmission or evasion 68,69. In the extremely virulent clinical strain of Mtb 
HN878 70, PGL overexpression led to the reduction of pro-inflammatory 
cytokines, whereas loss of PGL demonstrated a clear loss of virulence 71. 
The abundance of LOS in the capsular layer affects hydrophobicity of the 
membrane, with less observed LOS in more evolved mycobacterial 
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species such as Mtb leading to an increased hydrophobic membrane and 
presumably increased aerosol infectivity 72. PDIMs are major virulence 
factors in mycobacteria and have been implicated in a variety of functions. 
Early in establishing the infection, cell surface PDIMs recruit additional 
macrophages to the site of infection and shield the bacilli from the immune 
system by masking other pathogen associated molecular patterns 
(PAMPs) on the Mtb surface 73. Shielded from the immune system, the 
PDIMs protect Mtb from reactive nitrogen species which would otherwise 
be released by the macrophage, and lower the host release of tumor 
necrosis factor (TNF-α) and interleukin 6 (IL-6) 74. The permeability of the 
mycomembrane is also influenced by the presence of PDIMs, as mutants 
with impaired PDIM synthesis show increased uptake of the negatively-
charged probe chenodeoxycholate, as well as increased susceptibility to 
sodium dodecyl sulfate (SDS) 75. 
The low permeability of the myco-membrane would also seem to 
necessitate the use of porins or other outer membrane channels to assist 
in nutrient uptake, however very little is known about these postulated 
proteins. Recently, proteins of the proline-proline-glutamate family (PPE) 
have been identified in the outer membrane of M. tuberculosis which 
facilitate the acquisition of essential nutrients; PPE36 and PPE62 
demonstrate the ability to bind heme and represent one of the pathways 
for iron acquisition by M. tuberculosis76. Additionally, deletion of PPE51 in 
M. tuberculosis has resulted in mutants unable to grow on propionamide, 
glycerol, and glucose indicating its involvement in the uptake of these 
small nutrients77. 
The most well-documented of mycobacterial porins, MspA from M. 
smegmatis, has a unique goblet shape wherein the large open ‘lip’ of the 
goblet is oriented away from the cell, and the ‘stem’ of the goblet 
bottlenecks down to a size exclusion limit of 28 Å 78-81. This open pore size 
is more restrictive than that of other outer membrane pores from Gram-
negative bacteria, like TolC82,83 and FhuA84-86 which have openings of 35 
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Å and 4.5 nm respectively . There is no known MspA homolog in M. 
tuberculosis, however it does contain one confirmed outer membrane 
porin, an OmpA-like outer membrane channel which has not been shown 
to be essential for growth87, and whose role is still being investigated.  
 
1.3 – Mycolic Acid Synthesis and Transport 
 As the namesake of the CMN family outer myco-membrane, 
mycolic acids have a unique and essential pathway for their biosynthesis 
and incorporation. The overall size of the mycolic acid tail depends on the 
species within the CMN family; corynebacteria possess the shortest tails 
of 22-36 total carbons, nocardia species containing 46-60 carbons, and 
mycobacteria exhibiting the longest tails of 60-90 carbons in length88. This 
extensive lipid tail is synthesized in two parts, an alpha branch of 24-26 
carbons, and the mero-chain which varies from 48-62 carbons (Figure 
5)89. In M. tuberculosis, mycolic acid biosynthesis begins with Rv2524, a 
fatty acid synthase I (FAS I) enzyme containing the seven catalytic 
domains necessary for ‘eukaryotic-like’ fatty acid synthesis90. Two different 
products result from the FAS I enzyme, a 24-26 carbon acyl chain which 
undergoes carboxylation by AccD4 forming the alpha mycolic branch91, 
and a 16-18 carbon acyl tail which is fed into a FAS II system where the 
carbon tail is extended to 48-62 carbons. Initiation of the FAS II system 
requires the 16-18 carbon product of FAS I be activated by its addition to a 
malonyl group harbored by an acyl carrier protein (ACP)92,93. In contrast to 
the FAS I cycle, the FAS II system consists of discrete enzymes which 
catalyze each step of the elongation cycle: the activated acyl-ACP is 
reduced by MabA, which is then dehydrated by HadB and reduced by 
InhA, and then finally extended by two carbons via the addition of malonyl-
ACP by KasA94-97. Once the nascent mero-chain reaches sufficient length 
elongation ceases and the mero-chain is activated by the transfer of an 
adenyl monophosphate (AMP) by Fad3298, which then undergoes a 
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Claisen condensation with the carboxylated 24-26 carbon alpha branch 
via polyketide synthase 13 (pks13)99,100 (Figure 5).  
 
 
Figure 5 – Fatty Acid Synthesis (FAS) Pathway for Mycolic Acid 
Synthesis 
Acetyl-CoA and Malonyl-CoA feed into the multi-domain FAS I (Green) 
and the nascent fatty acid undergoes multiple rounds of elongation. Two 
main products result from FAS I, the C24-C26 α-mycolate branch and a 
C16-C18 acyl chain which feeds into the multi-protein FAS II Complex. 
Elongation by catalytic cycles of MabA (Yellow), HadB (Cyan), InhA 
(Brown), and KasA (Pink) continue until the complete mero-mycolate 
chain is formed. Pks13 (Salmon) catalyzes a condensation of the α-
mycolate and mero-mycolate to form the immature β-keto mycolic acid. 
 
 Trehalose-6-phosphate is also transferred by pks13 to the newly 
formed β-keto mycolic acid101, which is then reduced by corynebacterial 
mycolate reductase A (CmrA) forming the mature trehalose mono-
mycolate (TMM)102,103. Though in the final mature form, TMM has been 
shown to accumulate in the inner leaflet of the inner membrane unless the 
hydroxyl group on the mycolic motif is acetylated, which is carried out by 
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Trehalose mono-mycolate acetyl transferase (TmaT)104. Very recently a 
methyltransferase (MtrP) was discovered105 in the same genetic locus as 
TmaT, which when deleted also causes the accumulation on TMM in the 
inner leaflet of the plasma membrane, and whose function is shown to be 
required for regulation of TmaT. Acetylation of TMM is then followed by 
the transport of the mycolic acid to the periplasmic face of the cell by way 
of the essential Mycobacterial membrane protein large 3 (MmpL3)65,106-108 
(Figure 6).  
 
Figure 6 – TMM Processing and Export Pathway 
The immature β-keto mycolic acid formed by Pks13 (Salmon) is reduced 
on the mycolic motif by CmrA (Dark Green) before being acetylated by 
TmaT (Rose) and then exported to the periplasm by MmpL3 (Orange). 
 
Accumulation of TMM in the inner leaflet of the cytoplasmic 
membrane is also observed in cells where MmpL3 is depleted, indicating 
that the mycolic acid efflux is carried out only by MmpL3 which explains its 
essentiality109. Once in the periplasm, the mycolic acids must reach their 
site of incorporation on the distal ends of the arabinogalactan matrix, 
where the TMM is transferred to arabinogalactan or combined into TDM. 
Exactly how the extremely hydrophobic mycolic acids traverse the 
periplasmic space remains unknown, but upon reaching their destination 
they are utilized by different isoforms of the secreted antigen 85 (Ag85 
A/B/C) complex, which function as mycolyl transferases. Each isoform of 
Ag85 is capable of catalyzing either the transfer of mycolate to 
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arabinogalactan or the creation of TDM, but the substrate specificities and 
transfer efficiencies of each differ between homologs63,64. 
 
Figure 7 – Crystal structure of MmpL3 
Crystal structure of M. smegmatis MmpL3. Three domains are visible in 
the structure, a periplasmic face, transmembrane region, and cytoplasmic 
face. The transmembrane region consists of twelve transmembrane 
spanning (TMS) alpha helices located in the center of the structure. The 
crystal structure was also obtained in the presence of inhibitor SQ109 
bound (pink spheres) visualized in the cutaway image. 6-n-dodecyl-α, α-
trehalose (6-DDTre) detergent molecules bound to the structure in a 
suspected substrate binding site are visualized as grey sticks, and are 
found lateral to the TMS as well as occupying a hydrophobic pocket in the 
periplasmic domain. 
(PDB: 6AJF, Zhang et al. Crystal Structures of Membrane Transporter 
MmpL3, an Anti-TB Drug Target. (2019) Cell 176: 636-648) 
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1.4 – MmpL3 As a Novel Therapeutic Target 
 Over the past half century, the frontline medications available for 
the treatment of tuberculosis have not significantly varied from the 
standard HRZE regimen established in the 1960’s. Current treatment 
consists of two phases, a two month intensive phase requiring daily 
dosage of isoniazid (H), rifampin (R), pyrazinamide (Z), and ethambutol 
(E), followed by a four month continuation phase of daily isoniazid and 
rifampin110. This six-month treatment duration is effective at clearing Mtb 
infections assuming full drug susceptibility, however high levels of 
resistance to both isoniazid and rifampin have been observed and these 
multidrug (MDR) resistant clinical isolates require more extensive 
treatment durations, sometimes in excess of 24 months4. Combination 
therapy of drugs targeting different metabolic pathways is required due to 
the constant frequency of spontaneous mutation encountered in M. 
tuberculosis111.  
The unique biosynthesis of the myco-membrane is rich in essential 
enzymes, and many of the frontline drugs accordingly target aspects of 
cell wall biosynthesis. Isoniazid was shown to inhibit InhA112,113, part of the 
catalytic elongation cycle of the FAS II system, while ethambutol inhibits 
the proper synthesis of cell wall arabinogalactan which then impedes the 
incorporation of mycolic acid into the outer membrane114,115. Pyrazinamide 
is a neutral prodrug which can penetrate the hydrophobic membrane 
where it is activated by mycobacterial pyrazinamidase into pyrazinoic 
acid116. Importantly, pyrazinamide shows little activity against actively 
growing cells, instead performing its sterilizing activity on slow growing or 
metabolically inactive persistor cells117,118. Rifampin is a broad-spectrum 
antibiotic which performs its bactericidal function through the inhibition of 
RNA polymerase119; point mutations in RNA polymerase have been 
shown to lead to high levels of resistance to rifampin, which is a principle 
diagnostic phenotype for MDR-TB120.  
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 The emergence of multidrug-resistant (MDR) and extensively drug-
resistant (XDR) TB, along with the rising prevalence of extremely resistant 
NTM infections19,20 has prompted the need to develop new pharmaceutical 
countermeasures and discover new druggable targets in the CMN 
family121. MmpL3 has been identified as both a druggable and novel 
therapeutic target122, validated by both in-vitro studies108,123,124, and in-vivo 
mouse infection models125. Not surprisingly, significant efforts have been 
focused on finding small-molecule inhibitors which selectively inhibit this 
unique mycobacterial target126 as treatment options for mycobacterial 
pathogens are extremely limited127.  
Screening large compound libraries for active chemical compounds 
in Mtb identified several hits acting on MmpL3, however their specificity 
and mechanism of action remain unclear. The ethylenediamine 
SQ109128,129 was identified as an inhibitor of MmpL3 based on observed 
cell wall defects and spontaneous resistant mutants130, and has since 
completed a Phase 2b clinical trial where it was demonstrated safety and 
efficacy in combination for the treatment of MDR-TB131. The adamantyl 
urea compound AU1235 was identified during random library screening to 
have potency against Mtb, and the cell wall mycolate defects observed 
due to AU1235 treatment were used to initially determine the function of 
MmpL3 as the mycolic acid transporter in mycobacteria123,126,132. A novel 
pyrrole derivative, BM212 was shown to have good antitubercular activity, 
and surprisingly even better potency against NTM infections133,134. 
Membrane transporters of the Resistance-Nodulation-Division 
(RND) superfamily are efflux pumps which recognize a wide variety of 
substrates and provide significant antibiotic resistance in Gram-negative 
bacteria. They possess twelve transmembrane spanning alpha helices, 
with protruding periplasmic loops located between helices 1 & 2 and 7 & 8, 
and can function monomerically or in multimeric complexes. In Gram- 
negative bacteria, the RND transporter can function as part of a tripartite 
complex (see Figure 2 above) where the RND pump is located in the 
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plasma membrane, an outer membrane channel is located in the 
asymmetric outer membrane, and a membrane fusion protein connects 
the RND to the outer membrane channel. When the RND complex is 
assembled, it carries out the efflux of substrates captured from the 
periplasm or plasma membrane and pumps them through the outer 
membrane channel and out of the bacterial cell 135.  
The pumping mechanism of the RND transporter is achieved 
through the cycling of three conformations of each protomer: the initial 
loose (L) conformation allows potential substrates access to the vestibule 
inside the protomer where the binding site is not fully accessible yet, then 
the internal binding site expands allowing the substrates to bind tightly (T) 
to the protomer after which the vestibule closes off (O) and the substrate 
is extruded though the central channel and out of the cell through the 
outer membrane channel 136,137. Energy to drive these conformational 
changes derives from a proton-antiport mechanism along a highly 
conserved salt bridge along the transmembrane helix 4 and 10 
interface138. In the most studied RND transporter, AcrB from Escherichia 
coli, this salt bridge consists of the highly conserved functional residues 
D407, D408, and K940 which were identified as the protonation sites 
necessary for proton transport 138,139. In both the loose (L) and tight (T) 
protomer conformations, the positively charged K940 residue is stabilized 
between the two negative residues D407 and D408 which prevents their 
protonation. For substrate extrusion in the open (O) conformation, 
substrate binding causes a rotational shift (14o total) in transmembrane 
helix 10 moving the K940 residue which is then stabilized by another 
conserved essential residue T978, allowing the sequential protonation of 
the two aspartate residues 140. This model presents a reasonable 
H+:substrate anti-port mechanism through which substrate binding signals 
are coupled to proton transport, and mutagenesis studies on these 
essential residues have resulted in the inactivation of the transporter 138.  
18 | P a g e  
 
 The crystal structure of a C-terminally truncated MmpL3 from M. 
smegmatis (Figure 7)141 revealed that MmpL3 has twelve transmembrane 
helices with two periplasmic loops in a similar orientation as that found in a 
single protomer of a typical Gram-negative RND efflux pump. Earlier 
structural studies of MmpL3 suggested a homotrimer quaternary structure 
with central hydrophobic vestibule and an access pore located between 
protein subunits based on negative-EM staining and homology modelling 
142. It was observed that 6-n-dodecyl-α, α-trehalose (6DDTre), a mimic for 
the native TMM substrate, was found stabilized by hydrogen bonds to a 
hydrophilic opening located on the periplasmic face of the protein. In 
agreement with the classification of MmpL3 as an RND transporter and in 
comparison with AcrB, a highly conserved pair of Asp-Tyr residues were 
observed in the center of the transmembrane region along helix 4 and 
helix 10, and are believed to form the proton translocation pathway 141. As 
an RND transporter, it is expected that MmpL3 undergoes a 
conformational change cycle similar to the LTO conformations observed 
with AcrB, however this is currently unknown. 
In this same work, crystal structures of MmpL3 in complex with 
inhibitors SQ109 and AU1235 were obtained which revealed that the 
inhibitors bound directly between these Asp-Tyr pairs (Figure 8), with the 
nitrogen atoms on the inhibitor backbone coordinating to the aspartate 
residues in the proton transport pathway. This inhibitor binding would 
prohibit any H+ transport through the protein, and therefore inhibit a 
H+:substrate anti-port mechanism. Mycolic acid transport is highly 
conserved in members of the CMN family, with the principle mycolic acid 
transporter of corynebacteria being CmpL1142,143. The observed H+ 
translocation path in the MmpL3 crystal structure is also present in a 
homology model of CmpL1 (Figure 8) with a high degree of similarity.  
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Figure 8 – Inhibitor binding site of MmpL3 and CmpL1 
The crystal structure of M. smegmatis MmpL3 (Red ribbon) with the proton 
transport Tyr-Asp pairs visualized as yellow sticks. A homology model of 
CmpL1 (Blue ribbon) was overlaid with the Tyr-Asp residues visualized as 
purple sticks.  
  
 
Despite substantial progress in understanding the essential 
transport of mycolic acids, the exact mechanism by which the transporters 
recognize and transports TMM is still elusive. Due to the intrinsic 
complexity of the CMN family outer membrane, assessing direct 
interaction of inhibitor compounds with membrane proteins is a challenge, 
and thus far, the development of Mtb MmpL3 inhibitors has been based on 
screening for active compounds and then generating spontaneous 
mutants to identify drug targets. The current MmpL3 inhibitors being 
developed for clinical trials (AU1235, SQ109, BM212) all have divergent 
chemical scaffolds, yet isolated MmpL3 point mutants can convey 
resistance to multiple different pharmacophores. Additionally, the 
conserved inhibitor binding site between distant relatives in the CMN 
family suggests the possibility of broad-spectrum mycolic acid transport 
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inhibition. The result chapters reported in this dissertation reflect our work 
to address these outstanding questions and advance the development of 
anti-CMN family therapeutics.  
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Chapter 2 - Methods 
2.1 - Strains and growth conditions 
E. coli Rosetta (DE3) and E. coli C43 (DE3) cells were grown at 37 °C with 
shaking in LB broth. The avirulent strain M. tuberculosis H37Rv mc2 6206 
(ΔpanCD ΔleuCD) was grown at 37 °C in Middlebrook 7H9-OADC, 0.05 % 
tyloxapol supplemented with 0.2 % casamino acids, 48 μg/mL 
pantothenate and 50 μg/mL L-leucine. M. smegmatis mc2 155 was grown 
at 30 0C in Middlebrook 7H9 broth+10 % ADC supplement with 0.05 % 
Tween 80 with shaking. C. glutamicum strains: ATCC 13032 (WT), LY108 
(ΔCmpL1 ΔCmpL2 ΔCmpL3), LY109 (ΔCmpL2 ΔCmpL3 ΔCmpL4)143 
were grown at 30 0C in 2xTY media with shaking. For M. smegmatis, 
hygromycin B (50 g/ml) and kanamycin (25 g/ml) and for C. glutamicum 
kanamycin (25 g/ml) were used as selection markers. For E. coli 
kanamycin (50 g/ml) and ampicillin (100 g/ml) were used. 
 
2.2 - Protein purifications 
MmpL3 Purification 
Mtb MmpL3 was purified as follows. M. smegmatis MmpL3 cells 
harboring pMVGH1:MmpL3(tb) were inoculated into the 7H9-ADC medium 
supplemented with 0.2 % glycerol, 0.05 % Tween-80, 25 g/mL 
kanamycin, 50 g /mL hygromycin B, and incubated for 48 hours at 30 0C 
with shaking. The cell pellet from 1 liter culture was resuspended in 20 mL 
of TM Buffer (10 mM Tris-HCl (pH 8.0), 1 mM MgCl2) with 100 g /mL 
DNase I and 1.0 mM PMSF, and cells were broken with 3-4 passes 
through French Press (20,000 psi). Unbroken cells were removed via 
centrifugation at 16,000 x g, and membranes were collected by 
ultracentrifugation at 185,000 x g, at 4 0C for 1 hour. The membrane 
pellets were solubilized 4-12 hours at 4 0C in TS Buffer (20 mM Tris-HCl 
(pH 8.0), 150 mM NaCl, 2 % Triton X-100). Insoluble material was 
removed via ultracentrifugation at 185,000 x g, 4 0C for 1 hour, 
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supernatant was collected and NaCl concentration was increased to 200 
mM (final). The sample was then passed through a HiTrap Q-FF (5 mL - 
GE Healthcare) anion exchange column at a flowrate of 0.5 mL/min. Flow-
through was collected and adjusted to 400 mM NaCl and 10 mM imidazole 
(final concentrations) and loaded onto His-Bind affinity resin (Novagen). 
Column was washed two times with ten column volumes of TW Buffer (20 
mM Tris-HCl (pH 8.0), 400 mM NaCl, 20 mM imidazole, 0.2 % Triton X-
100), and then the column was washed two times with 10 column volumes 
of HW Buffer (20 mM HEPES-KOH (pH 8.0), 400 mM NaCl, 20 mM 
imidazole, 0.2 % Triton X-100). MmpL3 was then eluted in six fractions 
with 0.5 CV of HE Buffer (20 mM HEPES-KOH (pH 8.0), 400 mM NaCl, 
500 mM imidazole, 0.2 % Triton X-100). 
 
CmpL1 Purification 
C. glutamicum CmpL1 was purified as follows. 2xTY media (16 g tryptone, 
10 g yeast extract, 5 g NaCl per liter) was inoculated with LY108143 
harboring pAN6:CmpL1 overnight at 30 oC with shaking. The cells were 
sub-cultured 1:100 in fresh 2xTY media for two hours then induced via 
addition of 0.1 mM IPTG for an additional 2 hours at 30 oC with shaking. 
Each 1 L pellet was resuspended in 20 mL of TM Buffer (10 mM Tris-HCl 
pH 8.0, 1 mM MgCl2) with 100 g/mL DNase I and 1.0 mM PMSF, and 
cells were broken with 3-4 passes through French press. Unbroken cells 
were removed via centrifugation at 16,000 x g, and membranes were 
collected by ultracentrifugation at 185,000 x g, 4 0C for 1 hour. The 
membrane pellets were solubilized 4-12 hours at 4 0C in TS Buffer (10 mM 
Tris-HCl pH 8.0, 150 mM NaCl, 2 % Triton X-100). Insoluble material was 
removed via ultracentrifugation at 185,000 x g, 4 0C for 1 hour, 
supernatant was collected and flowed through a StrepTactin II (GE) 
column pre-equilibrated with TS buffer. The column was washed with TS 
buffer and protein was eluted in TE buffer (10 mM Tris-HCL pH 8.0, 150 
mM NaCl, 0.2 % Triton X-100, 2.5 mM desthiobiotin). 
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CrgA and Pks13 Purification 
M. tuberculosis CrgA (Rv0011c) and Pks13 (Rv3800c)) were purified as 
follows: 5 mL of E. coli Rosetta (BL21) cells harboring pET29a::crgA or 
pET26b::pks13 were grown in LB broth plus 25 g/mL kanamycin 
overnight at 37 oC. Cells were sub-cultured 1:100 in fresh LB broth plus 
kanamycin and grown to OD600 0.6-0.8, and then induced with 0.1 mM 
IPTG for 4 hours at 37 oC. Cells were harvested by centrifugation at 
16,000 x g for 20min, then resuspended in lysis buffer (50 mM Tris-HCl pH 
8.0, 5 mM EDTA, 1 mM PMSF) and broken via sonication. Unbroken cells 
were removed with centrifugation at 16,000 x g, and then membranes 
were collected by ultracentrifugation at 185,000 x g at 4oC for 1 hour. 
Membranes were solubilized with HS buffer (20 mM HEPES-KOH pH 7.4, 
150 mM NaCl, 2 % Triton X-100) overnight at 4 oC with stirring. Insoluble 
material was removed by ultracentrifugation at 185,000 x g at 4 oC for 1 
hour. Soluble sample were then loaded onto HIS bind resin and washed 
extensively with HW buffer (20 mM HEPES-KOH pH 7.4, 150 mM NaCl, 
0.2 % Triton X-100, + [20 column volumes of 20 mM imidazole then 6 
column volumes of 50 mM imidazole]), before final elution with HW + 500 
mM imidazole.  
 
Rv0207c and LprC Purification 
M. tuberculosis Rv0207c and LprC (Rv1275) were purified as follows. 5 
mL of E. coli Rosetta (BL21) cells harboring pET29a::rv0207c, or E. coli 
(C43) cells harboring pET14b::lprC, were grown in LB broth plus (25 
g/mL kanamycin or 100 g/mL ampicillin respectively) overnight at 37 oC. 
Cells were sub-cultured 1:100 in fresh LB broth plus appropriate antibiotic, 
and grown to OD600 0.6-0.8, and then induced with 0.1 mM IPTG overnight 
at 16 oC. Cells were harvested by centrifugation at 16,000 x g for 20 min, 
then resuspended in lysis buffer (50 mM Tris-HCl pH 8.0, 5 mM EDTA, 1 
mM PMSF) and broken via sonication. Unbroken cells were removed with 
centrifugation at 16,000 x g, and then membranes were collected by 
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ultracentrifugation at 185,000 x g at 4oC for 1 hour. Membranes were 
solubilized with HS buffer (20 mM HEPES-KOH pH 7.4, 150 mM NaCl, 2 
% Triton X-100) overnight at 4 oC with stirring. Insoluble material was 
removed by ultracentrifugation at 185,000 x g at 4 oC for 1 hour. Soluble 
samples were passed through a SP-HP cation-exchange column (GE 
Healthcare), and flow-through was spiked to 20 mM imidazole and 200 
mM NaCl (final concentrations) before loading onto HIS-bind resin. The 
column was washed extensively with HW buffer (20 mM HEPES-KOH (pH 
7.4), 150 mM NaCl, 0.2 % Triton X-100, + [20 column volumes of 20 mM 
imidazole then 6 column volumes of 50 mM imidazole]), before elution 
with HW buffer + 500 mM imidazole.  
 
MviN Purification 
M. tuberculosis MviN (Rv3910) was purified as detailed above for Pks13; 
with the only differences as follows: E. coli (C43) cells harboring 
pET29a::mviN were utilized, and cells were induced with 0.1 mM IPTG 
overnight at 37 oC. 
 
AftD and Antigen 85 
In addition to our five purified proteins (above), we also acquired the Mtb 
arabinosyl-transferase AftD which was purified by a collaborative research 
group of Filippo Marica (Columbia University, New York, NY). The antigen 
85 complex of secreted mycolic acid transferases was available 
commercially (BEI). 
 
2.3 - MIC assays 
Minimal inhibitory concentration (MIC) of compounds were determined as 
detailed previously126 for M. tuberculosis. C. glutamicum minimal inhibitory 
concentrations were obtained by serial two-fold dilution on 96-well plates 
which were incubated at 30 0C and analyzed visually for growth after 48 
hours143. 
25 | P a g e  
 
2.4 - SPR  binding assays 
A purified protein was amine-crosslinked to a flowcell of a CM5 Series S 
chip (GE Healthcare) which was activated with 0.05 M N-
hydroxysuccinimide and 0.2 M N-ethyl-N-(3-
diethylaminopropyl)carbodiimide (BIAcore). After immobilization, the 
remaining unreacted groups were quenched by the injection of 0.5 M 
ethanolamine HCl (pH 8.0). The immobilized baseline measurement and 
final binding assays were performed in running buffer containing: 25 mM 
HEPES-KOH (pH 7.0), 150 mM NaCl, 0.2 % Triton X-100, and 5 % 
DMSO. A second flowcell (to serve as a reference subtraction), was 
prepared in exactly the same manner, omitting protein during the 
immobilization step. A two-fold concentration series of inhibitors were 
prepared and injected sequentially in order of increasing concentration 
with a flowrate of 30 L/min, the injection phase lasting 30 sec 
(association) followed by a 60 sec collection of running buffer 
(disassociation). Sensorgram results were normalized to the initial blank 
injection which contained only running buffer, and then the reference 
flowcell sensorgram was subtracted from the protein sensorgram. Data 
was analyzed and fitted globally to 1:1 and Two-State binding models.  
          
For protein-protein binding interactions, injected proteins were 
concentrated to 10 M concentration, then a 2-fold dilution series was 
made with injections happening sequentially and in order of increasing 
concentration. SPR Assay Buffer was 20 mM HEPES-KOH (pH 7.4), 150 
mM NaCl, and 0.2 % Triton X-100, and proteins were injected at 10 
L/min for 30 seconds and then allowed to disassociate for an additional 
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180 seconds. Data was collected at 10 Hz at 20 oC, and all global data fits 
were made with a 1:1 binding model. SPR experiments were carried out 
using a Biacore T200 instrument of the Oklahoma Medical Research 
Foundation Biacore Facility, which is funded by the Shared 
Instrumentation Grant S10 OD025014. 
 
 Calculation of Maximum Response for SPR 
Formula for the calculation of the expected maximal response for a given 
Ligand:Analyte binding interaction during Surface Plasmon Resonance. 
RMax is the expected maximal response, RLigand is the amount of 
immobilized protein on the flow-cell surface, Binding Valency is the 
number of binding sites on the Ligand for each Analyte, and the final term 




2.5 - BLI binding assays 
Biolayer Interferometry (BLI) was performed using AR2G sensors loaded 
with purified MmpL3(tb) on an Octet RED96 instrument (ForteBIO). 
Sensors were hydrated for 1 hour and then activated for 600 seconds with 
20 mM 1-ethyl-3-(-3-dimethylaminopropyl) carbodiimide hydrochloride 
(EDC) and 10 mM Sulfo-N-hydroxysuccinimide (Sulfo-NHS) (AR2G 
Reagent Kit, ForteBIO). Activated sensors were loaded in wells containing 
the purified protein in sodium acetate buffer pH 4.0, then quenched for 
500 seconds in ethanolamine pH 8.0, and finally returned to assay buffer 
(20 mM HEPES-KOH pH 8.0, 150 mM NaCl, 0.2% Triton X-100). A 
second set of sensors, devoid of MmpL3(tb) protein, were activated as 
above and then quenched to serve as an empty sensor control for double-
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subtraction data processing (see second reference below). BLI binding 
assays were performed as follows: After sensor equilibration for 250 
seconds, a baseline was established in assay buffer for 60 seconds. 
Increasing two-fold dilutions of compounds were scanned for interaction 
with the proteins by first dipping into compound wells for 30 seconds, then 
returning to the baseline well and monitoring dissociation for 60 seconds. 
Sensors were dipped into fresh assay buffer and allowed to equilibrate for 
250 seconds between binding assay steps. Sensors were oriented so that 
a protein-loaded sensor was always dipped into fresh assay buffer while 
the other protein-loaded sensors were incubated with the test compounds 
(first reference). The entire assay was repeated with a set of sensors 
devoid of protein using the same compound plate after the assays with 
loaded sensors were complete (second reference). All assay steps were 
performed in the Octet RED96 instrument at 25 oC under agitation (500 
rpm). Assay development and data acquisition was performed using the 
BLI Acquisition Software 9.0.0.37 (ForteBIO). Data were processed and 
binding curves were globally fit using the BLI Analysis Software 9.0.0.12 
(ForteBIO) to 1:1 and Two-State binding models. 
 
 
2.6 - Partial Proteolysis 
Proteolysis of M. tuberculosis MmpL3 / MmpL3(G253E) was carried as 
follows. Purified protein was diluted in assay buffer (20 mM HEPES-KOH 
(pH 8.0), 150 mM NaCl, 0.2 % Triton X-100) to a final concentration of 100 
nM. Compounds were added to the protein samples to a final 
concentration of 200 M (solubility permitting) at 5 % DMSO and allowed 
to incubate for 5 min at room temperature before the addition of trypsin. A 
ten-fold trypsin gradient was performed for all tested compounds, and the 
digest was carried out for 30 min at 37 oC.  
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2.7 - Silver Staining 
Samples were separated via SDS-PAGE and visualized with silver-
staining as follows: SDS-PAGE gels were fixed for one hour at room 
temperature in 40 % methanol with 0.15 % formaldehyde. Gels were 
rinsed twice with water for five minutes, and then incubated for one minute 
in 1.25 mM sodium thiosulfate solution. After two brief 20 second rinses 
with water, gels were incubated for 10 minutes in 0.1 % silver nitrate. 
Lastly, gels were rinsed once with water for 20 seconds then developed (3 
% sodium carbonate, 250 M sodium thiosulfate, 0.075 % formaldehyde) 
until bands appeared, and the reaction was quenched by the addition of 
2.3 M citric acid. 
 
2.8 – Protein reconstitution into proteoliposomes and 
assays. 
 Reconstitution of MmpL3 was carried out as previously described144 
with modifications as follows. E. coli polar lipids (Avanti) were dissolved in 
chloroform and dried under vacuum overnight. Prior to reconstitution, 
lipids were resuspended in reconstitution buffer (25 mM HEPES-KOH (pH 
7.0), 1 mM DTT, 100 mM KCl) to a concentration of 20 mg/ml and 
sonicated briefly (Branson 1510 water-bath sonicator). 50 L of purified 
MmpL3 (350 g/mL) was mixed with 4 mg of dispersed lipids, and the 
volume was adjusted to 500 l via addition of reconstitution buffer + 1.1 % 
-OG145. Sample was incubated at room temperature for 10 minutes, then 
diluted slowly to 35 ml with prechilled reconstitution buffer and allowed to 
dialyze for 1 hour at 4 0C with stirring against reconstitution buffer + SM-2 
BioBeads (2 g/L)146. The sample was then ultra-centrifuged at 162,000 x g 
for 90 min, and the resulting pellet was resuspended in 200 L of 
reconstitution buffer. Pyranine was added to the sample at a final 
concentration of 2 mM, and the sample was extruded first through a 400 
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nm, then a 200 nm pore (Avanti Mini Extruder). Sample was then diluted 
to 2.5 mL with reconstitution buffer and passed through a PD-10 gel 
filtration column (GE Life Sciences) to remove untrapped pyranine. 
Control vesicles devoid of MmpL3 were prepared in parallel by the 
addition of reconstitution buffer in lieu of protein. For reconstitution assays 
with substrate analogs, 50 nM substrate was incubated with vesicles for 
five minutes prior to their addition to buffers, and data collection began 
immediately, and unless otherwise indicated inhibitor concentration in the 




2.9 - Homology Modelling 
The crystal structure of MmpL3 (PDB: 6ajf) was identified by the SWISS-
MODEL workspace as the closest match for the CmpL1 primary 
sequence. A homology model for CmpL1 was generated based on the 
crystal structure of MmpL3, with a GMQE of 0.72 and a QMEAN of -1.80. 
The homology model of CmpL1, along with the crystal structure of MmpL3 
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Chapter 3 - Purification and Functional 
Characterization of Mycolic Acid Transporters of 
Corynebacterium glutamicum and Mycobacterium 
tuberculosis. 
3.1 Introduction 
 Tuberculosis is the leading cause of infectious disease still afflicting 
a major percentage of the world, yet it is but one of many difficult to treat 
infections caused by the CMN family. To effectively combat these 
diseases we require additional, and more effective treatment options. An 
extensive search for new therapeutic targets against M. tuberculosis (Mtb) 
revealed that the essential membrane protein MmpL3 performed a unique 
role in the membrane assembly of mycobacteria, namely the transport of 
mature mycolic acids across the cellular membrane. Despite being highly 
conserved across mycolic acid containing species, a gap in the basic 
understanding of the mechanistic function of MmpL3-like proteins presents 
many challenges for therapeutic development. The physiological function 
of MmpL3 as the exporter of mycolic acids is well established. In these 
studies, we sought to reveal the biochemical mechanism by which MmpL3 
transports mycolic acids. Purification of membrane proteins presents its 
own challenges, which are further complicated in mycobacterial cells by 
the abnormally impermeable outer myco-membrane. To begin our study 
on the mechanism of mycolic acid transport, we purified the full-length 
CmpL1 from C. glutamicum and MmpL3 from M. tuberculosis. After 
purification was achieved, we assayed the proteins for function which was 
accomplished by the biochemical reconstitution into proteoliposomes. 
Upon successful reconstitution we were able to assess the proteins for 
their ability to facilitate H+ movement in the presence of substrate analogs. 
Here we report our results on the purification of CmpL1 and MmpL3, and 
successful incorporation of both into proteoliposomes. Our results with the 
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reconstitution of these proteins revealed the first mechanistic insight into 
their function as H+-dependent RND transporters. 
 
3.2 Results 
3.2.1 Purification of CmpL1 
 Corynebacteria possess the shortest length mycolic acids in the 
CMN family and accordingly have some of the simplest outer membranes 
to work with for the isolation of membrane components. C. glutamicum 
was chosen for the wealth of knowledge available due to its use 
commercially in the production of amino acids147, as well as its 
physiological similarity to pathogenic agents C. diphtheria and C. ulcerans. 
In C. glutamicum, CmpL1 is the MmpL3 analog and belongs to the 
Resistance-Nodulation-Division (RND) superfamily of membrane 
transporters143. As such, CmpL1 is an 83 kDa integral membrane protein 
possessing twelve transmembrane helices, with large periplasmic loops 
between helices 1 and 2, and 7 and 8. Negative-staining electron 
microscopy studies showed that CmpL1 exhibits a homo-trimeric 
quaternary structure 142. Based on homology with other RND transporters, 
we hypothesized that this transporter excretes mycolic acids via a H+-
coupled anti-port mechanism. 
 For the purification of CmpL1 we utilized wild type C. glutamicum 
ATCC 13032 strain harboring a corynebacterial expression vector pAN6 
carrying a copy of cmpL1 gene encoding a modified version of CmpL1 
containing a C-terminal eight amino acid strep-tag148. Expression of 
CmpL1 from the pAN6 vector was under the control of the lac promoter 
and induced by the addition of isopropyl β-d-1-thiogalactopyranoside 
(IPTG, Sigma). The expression of CmpL1 was confirmed by isolating the 
membranes and quantifying total membrane protein via a Bradford assay. 
After quantification, total membrane protein was normalized to 16 g per 
lane and analyzed by a 12% SDS-PAGE.  Protein was visualized by 
immunoblotting using a monoclonal anti-strep antibody, and 
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overexpression was observed as increased band intensity in the induced 
membranes, the results of which are shown in Figure 3.1A. 
 Once expression was confirmed, we continued the purification 
process, optimizing conditions for membrane solubilization and protein 
stability. Further optimization of the growth and induction conditions did 
little to increase the eventual yield of CmpL1, so we opted to scale-up our 
culture conditions instead, which resulted in a yield of 0.5 mg/L of CmpL1 
of cultured cells (Figure 3.1B).  
 
  
Figure 3.1 – Expression and Purification of corynebacterial CmpL1. 
A) Total membrane fractions of C. glutamicum were isolated from cells 
induced for the expression of CmpL1 with 0.1mM IPTG Samples were 
loaded at 16 g per lane on a 12% SDS-PAGE gel and visualized using 
anti-strep tag immunoblotting. ‘L’ is PageRuler Plus molecular weight 
marker, ‘U’ is the uninduced cells, ‘I’ are the induced cells. Molecular 
weight standards are indicated for 70 kDa and 100 kDa. Red asterisk 
indicates band for CmpL1. B) 10% SDS-PAGE of affinity purified CmpL1 
stained with Coomassie blue. Molecular weight standards are indicated for 
70 kDa and 100 kDa. FT: flow-through from Strep affinity column of 
solubilized membrane fraction, W1/W4 indicate wash fractions from Strep 
affinity column, Elutions (1-6) indicate sequential 0.5CV elution fractions 
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3.2.2 Purification of MmpL3 
 Mycolic acids of mycobacteria are among the longest of the CMN 
family, with the mero-chain often reaching approximately 80 saturated 
carbons in length, and when incorporated into the outer myco-membrane 
this creates a barrier of extreme impermeability. These extremely unusual 
lipid species are synthesized inside the mycobacterial cell before their 
transport across the plasma membrane through the action of 
Mycobacterial membrane protein large 3 (MmpL3). Similar in architecture 
to CmpL1, MmpL3 is also a large 100.3 kDa integral membrane protein of 
the RND class superfamily of transporters, with twelve transmembrane 
helices and protruding periplasmic loops between helices 1 & 2 and 7 & 8.  
 For the purification of MmpL3, we initially sought to keep our 
expression systems identical to the conditions used for CmpL1. We 
anticipated being able to use a recombinant corynebacterial expression 
system for MmpL3 due to the similar physiology and membrane structure 
shared between members of the CMN family. Therefore, we utilized C. 
glutamicum LY108 (CmpL1) harboring the pAN-6 expression vector 
carrying the full length MmpL3 gene from M. tuberculosis with a C-terminal 
strep tag. Proceeding from the previously established protocol for CmpL1, 
we confirmed weak expression of MmpL3 in the intact membrane fraction 
through separation by SDS-PAGE and western blotting (Figure 3.2A). We 
encountered problems when isolating MmpL3 from the corynebacterial 
membranes. SDS-PAGE analyses followed by immunoblotting showed 
severe MmpL3(tb) protein degradation (Figure 3.2B). Numerous 
optimization attempts were made to control this breakdown by varying the 
temperature of growth and assay conditions, as well as the addition of 
commercially available protease inhibitors. Despite these attempts, we 
were never successful in expressing intact MmpL3 in an appreciable yield 
from a corynebacterial host. Whether this was caused due to protein 
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misfolding in the recombinant system or proteolytic cleavage was 





Figure 3.2 – Expression and purification of MmpL3(Mtb) from C. 
glutamicum. 
 A) Total membranes of C. glutamicum induced expression of MmpL3 with 
0.1mM IPTG, loaded at 16 g per lane on a 10% SDS-PAGE gel and 
visualized using anti-strep tag immunoblotting. ‘L’ is PageRuler Plus 
molecular weight marker, ‘U’ is the uninduced cells, ‘I’ are the induced 
cells. Molecular weight standards are indicated for 70 kDa and 100 kDa. 
Red asterisk indicates band for MmpL3. B) 12% SDS-PAGE of affinity 
purified MmpL3 stained with Coomassie blue. Molecular weight standards 
are indicated for 70 kDa and 100 kDa. FT: flow-through from Strep affinity 
column of solubilized membrane fraction, W1/W5 indicate wash fractions 
from Strep affinity column, Elutions (1-6) indicate sequential 0.5CV elution 
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To achieve the purification of MmpL3, we changed our expression 
host from C. glutamicum to M. smegmatis (Msmeg), which is more 
physiologically similar to M. tuberculosis (Mtb). Knockout strains of Msmeg 
MmpL3 were shown to be viable when expressing a recombinant 
MmpL3(Mtb) .142 This result demonstrated that Mtb MmpL3 expressed in 
Msmeg is still intact and functional. Thus, our new expression system 
became M. smegmatis(mmpL3) harboring the mycobacterial expression 
vector pMVGH1 carrying MmpL3(Mtb) with an 8x histidine tag on the C-
terminus under the control of the hsp60 promoter. Immunoblot probing 
against the histidine tag confirmed protein expression and integrity, 
showing very little protein cleavage (Figure 3.3A). These results 
confirmed that the protein was more stably expressed in the mycobacterial 
system, and full purification of MmpL3(Mtb) was achieved with a final yield 




Figure 3.3 – Expression and Purification of MmpL3(Mtb) from M. 
smegmatis. 
A) Anti-His immunoblot of MmpL3(Mtb) protein purified by His-bind affinity 
chromatography and analyzed by 12% SDS-PAGE. FT: flow-through from 
His-bind affinity column, Elutions (1-6) indicate sequential 0.5 CV fractions 
containing 500mM imidazole. Molecular weight standards are indicated for 
70 kDa and 100 kDa.  B) 12% SDS-PAGE of purified MmpL3 stained with 
Coomassie blue. Lys: membrane fraction solubilized with 2% Triton X-100, 
AEX-FT: flow-through from Q-Sepharose anion exchange column, AEX-1: 
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wash fraction from Q-Sepharose column containing 400mM NaCl, AEX-2: 
wash fraction from Q-Sepharose column containing 1M NaCl. FT: fraction 
‘AEX-FT’ after passage through His-bind affinity column, W1/W4: 
sequential 10 CV wash fractions containing 20mM imidazole, Elutions (1-
6): sequential 0.5CV fractions containing 400mM imidazole. 
 
Section 3.2.3 – Reconstitution of CmpL1 and MmpL3 into 
proteoliposomes 
 In order to isolate and study the function of integral membrane 
proteins, they must first be liberated from the cell membrane and 
stabilized in an aqueous solution to allow biochemical assay. Traditionally 
this is accomplished by the use of a detergent or surfactant molecule in 
excess above the critical micellar concentration (CMC), which allows the 
solubilization of membrane components into detergent micelles. While 
useful for such applications as Surface Plasmon Resonance149, for the 
study of membrane transporter activity this becomes problematic as there 
is no defining membrane compartments through which to assess 
movement of substrates.  In these situations, it becomes necessary to 
reconstitute the protein into a lipid vesicle. Once the membrane proteins 
are incorporated back into lipids, the resultant proteoliposomes can then 
be subjected to tests for mechanistic function144-146. As MmpL3 and 
CmpL1 are members of the RND superfamily of membrane transporters, 
they are believed to function through H+-coupled transport of their 
substrates44,126,141,142. In order to test this hypothesis, we reconstituted 
both MmpL3 and CmpL1 into proteoliposomes and assayed their activity 
in the presence of a H+ gradient and tested them with a suspected 
substrate analog. 
Protein reconstitution followed the protocol detailed in Methods. 
Briefly, a purified protein was mixed with E. coli polar lipids (Avanti) and 
reconstitution buffer containing 1.1% -OG and allowed to mix briefly. The 
mix was then diluted 40-fold and then dialyzed against buffer without 
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detergent and containing SM2 Bio-Beads150 (Bio-Rad) to remove any 
residual detergent molecules, then proteoliposomes were collected via 
ultracentrifugation. To monitor proton translocation, we used 
pyranine151,152. Pyranine is a pH sensitive fluorescent probe which 
demonstrates signal quenching upon acidification, and which also cannot 
passively diffuse across lipid bilayers allowing it to remain trapped in the 
proteoliposomes and function as a monitor for H+ flux across our vesicle 
membranes, shown in Figure 3.4. Pyranine (Sigma) was added to 
reconstituted proteoliposomes, and the samples were passed through the 
polycarbonate membrane of a Mini-Extruder (Avanti) to a final diameter of 
200nm.  To remove any residual exterior pyranine, proteoliposomes were 
applied onto a PD-10 (GE Healthcare) desalting column, which traps small 
molecular weight solutes. Control ‘empty’ vesicles not containing protein 
were prepared in parallel, omitting protein from the reconstitution buffer.  
 
 
Figure 3.4 –Representation of a Reconstituted Membrane 
Transporter. 
A cartoon schematic of our testing conditions for the activity of mycolic 
acid transporters. Once trapped in the vesicle, pyranine is unable to 
diffuse out across the lipid membrane and serves as a fluorescent reporter 
for an internal pH change. Shown in A and B are the two orientations 
proteins can adopt during proteoliposome formation. 
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First, we assessed the successful reconstitution of protein into 
proteoliposomes in order to ensure that we are not measuring any H+ flux 
due to semi-permeable lipid bilayer. To achieve this, a set of parallel 
reconstitutions were performed with MmpL3, wherein we varied the 
amount of protein used during reconstitution and likewise we expected to 
recover protein from the proteoliposomes in a concentration dependent 
manner. As shown in Figure 3.5, we do not observe any protein in our 
empty control vesicles, while we observe a clear concentration dependent 
recovery of protein observed in the parallel reconstitutions. This result 
demonstrated that MmpL3 is reproducibly trapped in the lipid vesicles 
during reconstitution, and the subsequent data we acquire can be 
attributed to the activity of the protein in the lipid membranes. 
 
Figure 3.5 – Protein recovery after reconstitution. 
Reconstitution experiments E, 1 – 4 were carried out in parallel with 
increasing concentrations of MmpL3, where E: no protein control, 1: 2μg 
MmpL3, 2: 4μg MmpL3, 3: 8μg MmpL3, and 4: 16 μg MmpL3. Equal 
volumes (12 μL) of reconstituted liposomes were loaded onto 10% SDS-
PAGE and separated by electrophoresis before visualization by silver-
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staining. Molecular weight standards are indicated for 70 kDa and 100 
kDa. Reconstituted MmpL3 indicated by the band at the asterisk. 
  
Next, we sought to assay whether there was H+ flux through the 
mycolic acid transporters in the presence of a H+ gradient, which was 
achieved by monitoring the pyranine fluorescence over a five-minute 
period. As pyranine is trapped in the lumen of the vesicles, when we 
incubate the vesicles in buffer with a differing extravesicular pH, any H+ 
movement into the vesicles will quench the fluorescent signal, and 
likewise H+ flux out of the vesicles will result in increased fluorescent 
signal.  
When protein-free vesicles with entrapped pyranine were pre-
equilibrated in the pH 7.0 buffer, and then diluted into the pH 6.0 buffer or 
the pH 8.0 buffer, the pyranine fluorescence (therefore intravesicular pH) 
did not change significantly during the five minute experiment, suggesting 
that spontaneous leakage of H+ in the reconstituted vesicles was 
negligible (Figure 3.6A).  
MmpL3-containing vesicles reported no H+ movement at the neutral 
pH, while reporting H+ influx in the acidic conditions, and a comparable 
level of H+ efflux when the extravesicular buffer was alkaline (Figure 
3.6B). CmpL1 showed a similar H+ influx to MmpL3 under acidic 
conditions, yet differed by also reporting a slight influx at neutral pH and 
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Figure 3.6 – Reconstituted mycolic acid transporter activity at 
different pH conditions. 
A) Control vesicles with protein omitted during reconstitution show no 
change in fluorescence, indicating vesicles are formed with tight lipid 
packing and are not permeable to H+. B) Reconstituted MmpL3 vesicles 
show H+ flux in the direction of the gradient. C) Reconstituted CmpL1 
vesicles show different H+ flux behavior. Pyranine excitation was at 455 
nm and emission was measured at 509 nm for five minutes at 25oC. Grey 
Line: alkaline pH 8.0, Orange Line: neutral pH 7.0, Blue Line: acidic pH 
6.0. Error bars are standard deviations (n = 3). 
 
 
 It was observed in the crystal structure published of MmpL3141 that 
there were molecules of 6-n-dodecyl-α, α-trehalose (6-DDTre)  bound in a 
hydrophobic pocket in the periplasmic domain which could potentially 
function as an exit site during mycolic acid transport. To begin exploring 
potential substrate activities of MmpL3, we attempted to mimic the native 
substrate Trehalose Mono-Mycolate (TMM) with compound AcTre67 
(Figure 3.7), which possesses a palmitic acid esterified to a trehalose 
head group. For this assay we incubated the proteoliposomes with 
AcTre67 prior to their addition to the differing pH buffers and monitored 
the fluorescence. When a substrate analog AcTre67 (Figure 3.8A) 
containing a trehalose headgroup acylated with a 16-carbon long tail was 
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added to the vesicles at the three different external pH, the lipid bilayer did 
not show significant changes in leakiness when compared to vesicles in 
the absence of the AcTre67 (Figure 3.6A). AcTre67 (0.05 M) did not 
affect fluorescence when added directly to a solution of pyranine. The 
same results were obtained for other substrate mimetics of the 
MmpL3/CmpL1 pumps containing C4 (AcTre246), C10 (AcTre243), C12 





Figure 3.7 – Substrate analogs for Trehalose monomycolate (TMM) 
Substrate analogs for TMM were generated by the esterification of fatty 
acids with varying length acyl tails to trehalose disaccharides. 
  
MmpL3-containing proteoliposomes exhibited no significant H+ 
movement when mixed with the buffer at the neutral pH. However, the 
fluorescence of entrapped pyranine either increased or decreased when 
proteoliposomes were added into the pH 8.0 or the pH 6.0 buffer, 
respectively (Figure 3.6B), suggesting that in the presence of ΔpH, the 
reconstituted MmpL3 facilitates fluxes of H+ across the membrane. 
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Importantly, this transport of H+ was stimulated in the presence of the 
substrate AcTre67, as seen from the increased rates of pyranine 
fluorescence changes (Figure 3.8B).  
In the early stages of proteoliposome formation the detergent-lipid-
protein mixture is diluted well below the CMC of the -octyl-glycoside 
detergent, which is used to promote the spontaneous aggregation of the 
lipids into vesicles where the protein is stabilized by, and then trapped in, 
the lipid bilayer as the detergent is diluted out. Lacking other forces 
guiding the vesicular formation, protein orientation in the final vesicles 
would be mostly sterically controlled, and a mixture of the two protein 
orientations can be expected. Working with the hypothesis that MmpL3 
functions as a lipid-H+ anti-porter, these observed results indicate that 
MmpL3 stably inserted into our lipid vesicles in both orientations and can 
function as a H+ pump in each direction. The rates of fluorescence 
changes were comparable in the pH 6.0 and pH 8.0 buffers, which is also 
consistent with a random orientation of the protein in proteoliposomes and 
suggests MmpL3 in both orientations is functional after reconstitution into 
proteoliposomes.  
Since AcTre67 is expected to intercalate only into the outer leaflet  
phospholipid bilayer of the proteoliposomes, and its spontaneous flip-flop 
is expected to be very slow due to the presence of the trehalose 
headgroup, it is likely that the substrate stimulates the activity of the 
MmpL3 fraction with the substrate binding site accessible from the outer 
leaflet of the membrane. 
 The properties of the reconstituted CmpL1 differed from those of 
MmpL3. We found that CmpL1 proteoliposomes exhibited similar H+ influx 
in both the pH 6.0 and the pH 7.0 buffers, whereas no significant proton 
flux could be detected in the pH 8.0 buffer (Figure 3.6C). This result 
suggested that either the majority of the CmpL1 reconstituted into the 
proteoliposomes is in an inside-out orientation, or that only the protein 
molecules in the inside-out orientation are functional. Surprisingly, 
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AcTre67 as well as other analogs did not stimulate the proton flux activity 





Figure 3.8 – MmpL3 and CmpL1 proton translocation activity in the 
presence of a substrate analog AcTre67. 
This assay was carried out as detailed in Figure 3.6, with the exception 
that all vesicles were incubated with 50 nM AcTre67 for five minutes prior 
to their addition to the different pH buffers. A) Empty control vesicles. B) 
Pyranine fluorescence of MmpL3 vesicles incubated with substrate 
analog. C) Reconstituted CmpL1 vesicles incubated with substrate analog. 
Grey Line: alkaline pH 8.0, Orange Line: neutral pH 7.0, Blue Line: acidic 
pH 6.0. Error bars are standard deviations (n = 3). 
 
 To quantify these observed results, the obtained experimental 
curves were fitted into a logarithmic equation, and the rates of 
fluorescence change per second were extracted and plotted with the 
standard deviation from three independent experiments. Comparing the 
rates of the test conditions grouped together by pH (Figure 3.9) we see 
that MmpL3 can transport H+ without the presence of the substrate, 
however this activity is stimulated and increased in the presence of the 
substrate in both directions. CmpL1 was able to transport H+ into the 
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vesicles at both acidic and neutral pH, but there was no observed 
stimulatory effect of the substrate addition on the H+ transport ability. Side-
by-Side comparison of the vesicles +/- substrate shows a clear stimulatory 
activity of AcTre67 in MmpL3, with higher rates of transport of H+ into and 




Figure 3.9 – Rates of proton transport of MmpL3 and CmpL1 in the 
presence of a substrate AcTre67. 
Experimental data of fluorescence response as a function of time were 
fitted to a logarithmic equation, and the slopes were extracted as the Rate 
of Transport of H+ across the lipid bilayer in RFU/second, with error bars 
as SD (n=3). Extravesicular buffer conditions are grouped by color- Red: 
acidic pH 6.0, Grey: neutral pH 7.0, and Blue: alkaline pH 8.0.  
 
 
In effort to find a better functional substrate for CmpL1 than 
AcTre67, we tested the activity of a series of analogs with a similar 
trehalose head group but varied in acyl tail length. As CmpL1 only 
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exhibited H+ flux in the acidic extravesicular buffer, we tested the activity 
of these substrates for activity with CmpL1 and MmpL3 in the pH 6.0 
buffer as detailed above, with the results shown in Figure 3.10. The C16 
tail of AcTre67 had the least activity of all the substrates in CmpL1 with no 
significant transport activity of the intermediate length substrates (C10 / 
C12 / C14), however the shortest substrate C4, had a modest stimulatory 
effect on CmpL1 activity (Figure 3.10A). MmpL3 performed with the 
highest activity with the C16 tail of AcTre67, yet showed significantly less 
H+ flux with the new shorter-tailed substrates. The intermediate length 
substrates appear to inhibit H+ flux through MmpL3 as the rates of 
transport fall well below the non-substrate treated control, with the shorter 




Figure 3.10 - The effect of TMM analogs on the proton transport 
activity of the transporters.  
Proteoliposomes were incubated with a series of substrate analogs and 
assayed for transport activity in pH 6.0 buffer. Rates of proton transport 
were normalized to passive H+ flux in untreated vesicles. A) CmpL1 (Blue 
bars) exhibited no significant effect of the intermediate or longer 
substrates but its transport activity was stimulated upon the addition of the 
shortest C4 substrate. B) MmpL3 (Red bars) showed significant transport 
activity with the C16 tailed substrate, and inhibition of H+ flux with the 
intermediate length C10-14 carbon tails. Error bars are SD (n=3). 





Section 3.2.4 – Interaction of AcTre67 with CmpL1 and MmpL3 
 
Because AcTre67 (C16) was developed as a mimic for TMM in 
mycobacteria, it was possible that the lack of transport activity measured 
with CmpL1 is due to it not being able to interact with the transporter. 
Therefore, in order to see whether this substrate mimic would specifically 
interact with the mycolic acid transporters, we utilized a Surface Plasmon 
Resonance (SPR) assay and tested MmpL3 and CmpL1 for specific 
binding with AcTre67.  
For this assay, purified CmpL1 and MmpL3 were immobilized in 
separate flow cells of a CM5 Series S chip (GE Healthcare) and 
increasing concentrations of analyte (AcTre67) were injected over the 
chip. As anticipated, AcTre67 does specifically interact with MmpL3 as 
shown in Figure 3.11A, and no binding activity was observed with CmpL1 
in this assay Figure 3.11B. A possible explanation for this is the natural 
size discrepancy in TMM versus TMCM (trehalose mono-coryne 
mycolate), where the mycobacterial mycolic acid species are generally 
longer in both the -branch and mero-chain as compared to the shorter 
mycolic acids found in corynebacterial species. This hypothesis is yet to 















Figure 3.11 – Direct interaction of AcTre67 with MmpL3 
SPR sensorgrams of the direct interaction of injected AcTre67 with 
MmpL3 and CmpL1 immobilized on an CM5 Series S chip. Experimental 
curves (black) were obtained for an AcTre67 concentration series of 
400M (top concentration) and serial two-fold diluted down to 12.5M 
(bottom concentration). A) Curves were globally fit to a simple 1:1 binding 
model which yielded an experimental KD of 6.8M for MmpL3. B) No 
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Chapter 4 – Direct interaction and inhibition of 





 With the ultimate goal to inhibit mycolic acid transport 
pharmaceutically in order to finally eliminate these persistent human 
diseases, the next major gaps in knowledge that needed to be addressed 
are: how to know if the compounds developed as MmpL3 inhibitors are 
directly interacting with their target, and what is the molecular mechanism 
of their action? To answer these questions, we purified MmpL3 and 
CmpL1 and immobilized the proteins for use in a Surface Plasmon 
Resonance (SPR) instrument, which allowed us to monitor specific 
interactions of small molecules with the protein directly. Additionally, by 
using transporters reconstituted into proteoliposomes, the complicating 
off-target effects from the whole cell are removed, and we can identify 
inhibitory activity specific to a compound’s interaction with MmpL3. In this 
chapter we report our results on the development of a compound 
screening assay to identify potential mycolic acid transport inhibitors, and 
the direct binding of those inhibitory compounds to MmpL3 and CmpL1. 
We then describe whether transport activity of a substrate analog could be 
stopped by the presence of suspected MmpL3 inhibitors in a reconstituted 
proteoliposome. Building the ability to inhibit mycolic acid transport across 
the Corynebacterium-Mycobacterium-Nocardia family will help lead the 









4.2.1 – In Vivo Activity of Mycolic Acid Inhibitors against CmpL1 and 
MmpL3. 
 Previous studies showed that two of the four CmpL proteins, 
CmpL1 and CmpL4, are functionally redundant in the export of trehalose 
mono-corynemycolate (TMCM), and that only the double knockout mutant 
in genes encoding these proteins is non-viable143. We next used a panel 
of structurally diverse MmpL3 126 inhibitors (Figure 4.1), as well as a 
series of novel indole-2-carboxamide (IC) inhibitors, pyrrole-2-
carboxamides (PC), and imidazole-2-carboxamides (ImC), to identify 
those with narrow and broad specificity against these transporters. For this 
purpose, we used C. glutamicum WT ATCC 13032 and triple knockout 
mutants LY108 (cmpL1, cmpL2, cmpL3) and LY109 (cmpL2, 





Figure 4.1 – Published MmpL3 Inhibitors 
Compounds that have been pharmaceutically developed as MmpL3 
inhibitors. Compounds were identified during screening for in vitro activity 
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and assigned as inhibitors of MmpL3 based on spontaneous resistance 
mutations mapping to MmpL3. 
 
Minimum inhibitory concentrations (MIC) of the inhibitors were 
measured using a serial two-fold broth dilutions for WT C. glutamicum 
ATCC 13032, LY108 (CmpL4 dependent), LY109 (CmpL1 dependent), 
and M. tuberculosis H37Rv mc2 (Table 1). SQ109 and BM212 compounds 
inhibited the growth of all tested strains, pointing to their broad, 
transporter-independent activity. In contrast, the tetrahydropyrazolo[1,5-
a]pyrimidine-3-carboxamide THPP-1, as well as NITD-304 and NITD-349 
and most of the other compounds from the IC series, inhibited growth of 
M. tuberculosis at low micromolar concentrations but had no activity 
against the C. glutamicum strains (MIC values over 500 M). However, 
one pyrrole-2-carboxamide (PC88) and three representatives of the IC 
series IC4, IC21 and IC52 (Figure 4.2) inhibited the growth of C. 
glutamicum LY109 strain at low and mid micromolar concentrations. 
These compounds have similar nitrogen containing backbones as 
inhibitors SQ109 and AU1235 which were observed in the crystal 
structure of MmpL3 occupying the inhibitor binding site. Due to the 
conservation of binding sites between MmpL3 and CmpL1 (Figure 8), it is 
expected that these novel IC inhibitors bind to the same site in both 
MmpL3 and CmpL1. 
Thus, in addition to Mtb MmpL3, these compounds specifically 
target CmpL1, albeit with different efficiencies. Both IC4 and IC21 show 
nanomolar MICs against H37Rv mc2 and hence MmpL3, and are the best 
inhibitors of C. glutamicum LY109 and hence CmpL1 with MICs of 4 M 
and 32 M, respectively (Table 4.1). IC52 has MIC of 32 M against 
CmpL1, yet no measured inhibitory activity against Mtb MmpL3, whereas 
PC88 is active against both at micromolar concentrations.  
Taken together, these results show that the analyzed inhibitors vary 
in their target specificities, with most of the inhibitors effective only against 
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Mtb and MmpL3. SQ109 and BM212 have broad specificity, and in 
addition to MmpL3 act against both CmpL4 and CmpL1. A few are 
specifically active against CmpL1 and MmpL3, while only IC52 seems to 
be more specific to CmpL1. Since CmpL1 and CmpL4 are 
interchangeable in their physiological functions, these results further 
suggest that the mechanism of action of these inhibitors is sensitive to the 




Figure 4.2 - Novel indole-2-carboxamide Inhibitors  
Novel inhibitory compounds with activity against M. tuberculosis which 
were identified to have selective activity against C. glutamicum mutants 
dependent upon CmpL1 for viability. Novel IC and PC inhibitors in this 
thesis were generated by the North lab at Creighton University. AU1235, 
BM212, SQ109, NITD304, NITD349, and THPP-1 were donated by the 
Jackson lab at Colorado State University.  
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Table 4.1. Minimum Inhibitory Concentrations (MIC) of MmpL3 
inhibitors in M. tuberculosis and C. glutamicum. Two-fold serial broth 
dilution assays were repeated on three independent dates, and reported 
values are in micromolar concentrations. 
 
 
4.2.2 Direct Interaction of Inhibitors with Targets 
 Inhibitors acting specifically on MmpL3 and CmpL1 are expected to 
directly bind to the target proteins. We next used the SPR assay defined in 











IC2 1.02 >500 >500 >500 
IC4 0.05 >500 >500 4 
IC5 1.32 >500 >500 >500 
IC10 >38.7 >500 >500 >500 
IC12 19.50 >500 >500 >500 
IC21 0.07 >500 >500 31.2 
IC 41 1.09 >500 >500 >500 
IC 42 > 17.45 >500 >500 >500 
IC43 > 15.98 >500 >500 >500 
IC46 0.48 >500 >500 >500 
IC 50 0.12 >500 >500 >500 
IC52 >16.21 >500 >500 31.2 
IC65 6.17 >500 >500 >500 
PC88 8.12 >500 >500 65.2 
IC90 54.02 >500 >500 >500 
PC91 32.50 250 250 250 
IC92 12.34 >500 >500 >500 
PC96 155.23 >500 >500 >500 
SQ109 1.82 125 62.5 62.5 
BM212 19.36 30 30 30 
NITD304 0.01 >500 >500 >500 
NITD349 0.03 >500 >500 >500 
THPP-1 5.38 >500 >500 >500 
AU1235 1.2 >500 >500 >500 
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Chapter 2.4, to compare binding mechanisms and affinities of inhibitors 
with broad and narrow target specificities. We used this approach to 
analyze the direct interaction of several pharmaceutically pursued MmpL3 
inhibitors with purified MmpL3 and purified CmpL1. For this purpose, both 
CmpL1 and MmpL3 proteins were purified from C. glutamicum LY108 
carrying pAN6:CmpL1 and M. smegmatis mc2 155(ΔMmpL3) carrying 
pMVGH1:MmpL3(tb) respectively and immobilized onto adjacent flow cells 
of the same CM5 Series S sensor chip (GE Healthcare). We found that 
the AU1235, SQ109, and BM212 inhibitors all bound both MmpL3 and 
CmpL1 with micromolar affinities (Table 4.2). Interestingly, these inhibitors 
bound to CmpL1 with nearly identical binding mechanisms and affinities 
(Figure 4.3). These results are in agreement with the broad target 
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659 349 40.3 115 
 
Table 4.2. Kinetic profiles of compounds interacting with MmpL3 and 
CmpL1. Binding data was obtained via Surface Plasmon Resonance 
(SPR) by sequential injection of increasing compound concentration, and 
sensorgrams were globally fit to a 1:1 binding model. 
 
 
Figure 4.3 - Binding of MmpL3 inhibitors to MmpL3 and CmpL1.  
A) Binding interactions of MmpL3 inhibitors with purified MmpL3. B) 
Binding interactions of MmpL3 inhibitors with purified CmpL1. Compounds 
were injected at a 30 μl/min flowrate in sequentially increasing two-fold 
concentrations. The top concentration of AU1235 and SQ109 injected was 
400 M while the top concentration of BM212 injected was 60 M (based 
on max solubility at 5% DMSO experimental conditions.) Black lines are 
experimental data, while Red Lines are curves global fit to a 1:1 binding 
model. Rates and affinities can be found in Table 4.2. 
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 We next analyzed binding affinities of IC4, IC21, and IC52 with the 
lowest MICs against LY109 to MmpL3 and CmpL1 proteins. All three 
compounds bound to both transporters. For both CmpL1 and MmpL3, we 
again found nearly identical binding profiles for these compounds (Figure 
4.4). Surprisingly, IC52 binds to both CmpL1 and MmpL3 with similar 
kinetics, yet MIC measurements suggested a somewhat better specificity 
to CmpL1.   We then analyzed the interactions of transporters with the 
IC52 structural analogs IC5 and IC46, which are active against Mtb 
MmpL3 but have no growth inhibitory activities against C. glutamicum 
strains. We found that IC5, IC52, and IC46 exhibit remarkably different 
binding activities (Figure 4.5). Removal of the methylene linker prior to the 
adamantyl group in IC5 almost completely removes binding interaction 
with MmpL3. Although adding two methyl groups on the indole ring in IC46 
also negatively impacts the maximal binding response (RU) when 
compared to IC52, the compound has similar affinities to both MmpL3 and 
CmpL1.  Thus, there is no direct correlation between binding interactions 
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Figure 4.4 - Binding of novel IC compounds to transporters with 
selective in vivo activity against CmpL1. A) Binding interactions of 
novel IC inhibitors with purified MmpL3. B) Binding interactions of novel IC 
inhibitors with purified CmpL1. All compounds were injected at a 30 μl/min 
flow rate in sequentially increasing two-fold concentrations, with the top 
concentration injected at 400 M for all IC inhibitors. Black lines are 
experimental data, while Red Lines are curves global fit to a 1:1 binding 
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Figure 4.5 - Binding activity of structurally similar compounds to 
transporters.  
In this assay compounds with similar chemical scaffolds were monitored 
for binding activity with MmpL3. Compounds were injected at a 30 μl/min 
flowrate in sequentially increasing twofold concentrations, from 12.5 M to 
400 M. Black lines are experimental readings, while Red Lines are 
curves global fit to a 1:1 binding model. 
 
 
4.2.3 - Inhibition of Proton Transport Activity 
 Next, we sought to test if our small molecule inhibitors which 
showed direct interaction with CmpL1 and MmpL3, as well as activity 
against both coryne- and myco- bacteria, could functionally inhibit 
substrate transport in CmpL1 and MmpL3. To test this hypothesis, we first 
incubated protein reconstituted into proteoliposomes with substrate 
AcTre67, then added them to buffers containing an inhibitor and 
measured the fluorescence change as described in Chapter 3. Control 
protein-free vesicles incubated with AcTre67 and treated with the 
inhibitors IC21, IC52, and IC4 show no significant H+ flux in the testing 
conditions, therefore the MmpL3 and CmpL1 results were normalized to 
the control vesicles. MmpL3 experiences inhibition of H+ movement with 
all three inhibitors at pH 6.0, while only showing inhibition with IC52 at pH 
8.0 and showing no inhibition at pH 8.0 with both IC21 and IC4 (Figure 
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4.6A). CmpL1 vesicles show a slight inhibition of H+ flux at pH 6.0 with all 
three inhibitors, and H+ flux was observed out of the vesicles at pH 8.0 in 
the inhibitor treated vesicles. (Figure 4.6B) 
 
Figure 4.6 - Differential proton transport inhibition in opposite protein 
orientations.  
A) MmpL3 vesicles incubated with AcTre67 for five minutes then assayed 
for transport inhibition in different pH buffers (Red Bars – pH 6.0, Grey 
bars – pH 7.0, Blue bars – pH 8.0). B) CmpL1 vesicles treated as 
described in A. Rates of transport were obtained by fitting experimental 
fluorescence change over time curves to a logarithmic equation and 
extracting the slope. Error bars are SD (n=3). 
  
 
To analyze the dose-dependency of this inhibition, we pre-
incubated MmpL3- and CmpL1-containing proteoliposomes, and empty 
control vesicles equilibrated in the pH 7.0 buffer, with the substrate 
AcTre67 and then mixed them into buffers containing increasing 
concentrations of inhibitor and measured the change in pyranine 
fluorescence and hence proton flux as described earlier. The control 
empty vesicles pre-incubated with AcTre67 and then exposed to the 
inhibitors IC21, IC52, and IC4 show no significant proton flux under the 
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testing conditions, suggesting that neither the substrate nor the inhibitors 
affect the integrity of the phospholipid bilayer of the vesicles (Figure 4.7 – 
Black Lines).  
In contrast to the control experiment, the proton-translocating 
activity of MmpL3 was inhibited by all three inhibitors (Figure 4.7 – Red 
Lines). In the pH 6.0 buffer, IC4 and IC21 inhibited proton-translocating 
activity of MmpL3 in a concentration-dependent manner. Furthermore, at a 
concentration of 100 nM, IC4 reduced the proton flux in MmpL3-containing 
proteoliposomes to the background level of the control empty vesicles. In 
contrast, even at the highest tested concentration of 100 nM, the rate of 
proton flux decreased by 4-fold in the presence of IC21 when compared to 
the no inhibitor control, but it was still above the empty vesicle control. 
Finally, the inhibitory effect of IC52 was the same at the three tested 
concentration reducing the rate of proton flux by 3-fold. This result 
suggests that not all MmpL3 molecules are inhibited by IC52 under these 
conditions. Surprising, only IC52 exhibited an inhibitory activity when the 
assays were carried out in the pH 8.0 buffer, whereas neither IC21 nor IC4 
inhibited the reconstituted MmpL3 in the pH 8.0 buffer (Figure 4.6A). 
Furthermore, IC21 appears to stimulate the proton efflux from the 
proteoliposomes. This result suggests that either the activity of inhibitors is 
sensitive to pH due to the presence of ionizable groups on the inhibitor 
backbone, or that the inhibitors have an affinity for a specific orientation of 
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Figure 4.7 – Dose dependent inhibition of proton translocating 
activities of MmpL3 and CmpL1.  
A) Control empty vesicles (black line), CmpL1 proteoliposomes (blue line), 
and MmpL3 proteoliposomes (red line) were incubated with AcTre67 for 5 
min and then added to the pH 6.0 buffer containing IC21 at two-fold 
increasing concentrations. Fluorescence of entrapped pyranine was 
monitored for five minutes at 25oC. Rates of transport were calculated and 
plotted as a function of inhibitor concentration. Error bars are SD (n = 3). 
B) The same as in A but buffer was supplemented with IC52. C) The 
same as in A but buffer was supplemented with IC4. 
 
 
4.2.4 – Mechanism of Resistance to MmpL3 Inhibitors 
A major hurdle for any antibiotic research is the emergence of 
resistance, and resistance to MmpL3 inhibition has, unsurprisingly, 
already been observed. Several spontaneous mutants exhibiting 
resistance to novel MmpL3 inhibitors have been clinically isolated and the 
mutant polymorphisms primarily localize around the transmembrane 
region of MmpL3 (Figure 4.8). A single point mutation in MmpL3 identified 
by the Mary Jackson group at Colorado State University, G253E has been 
shown to confer resistance to all the currently described MmpL3 inhibitors 
(Table 4.3), the mechanism which is of great interest.  
 







Figure 4.8 – Point mutations in MmpL3 map to the Transmembrane 
Region. Isolated point mutations from M. tuberculosis which convey 
resistance to MmpL3 inhibitors were aligned to the crystal structure of 
MmpL3 from M. smegmatis. Mutated residues in Mtb MmpL3 (left column) 
were aligned to their respective residues in M. smegmatis (center column) 
and represented as colored spheres on the crystal structure for M. 
smegmatis MmpL3, with the exception of Q372R which was located in an 
unresolved loop and not included in the crystal structure. All mutations 
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L189R 8x 8x  4x 4x 4x 
G253E 4x 4x  8x 8x 8x 
S288T  8x 4x 8x 8x 8x 
S309C 8x 8x  4x 8x 8x 
T311I 4x   4x   
Q372R     8x 8x 
L567R 4x 4x   8x 8x 
S591I 8x 8x 4x 8x 4x 8x 
F644C 8x 4x     
V684G    8x 4x 4x 
V684A    4x 8x 8x 
 
Table 4.3 – Resistance profiles of clinically isolated MmpL3 mutants. 
Comprising the table are MIC fold changes of the inhibitors when 
compared to wildtype MmpL3. Red boxes indicate an eight-fold or higher 
increase in MIC, Orange boxes are a four-fold or higher increase, and 
Grey boxes are a negligible two-fold or lower change in MIC. MmpL3 
mutants and MIC data from Mtb strains generated by the Mary Jackson 
research group at Colorado State University. 
 
To investigate how the MmpL3(G253E) singular point mutation 
could confer resistance to such different chemical scaffolds, we purified 
MmpL3(WT) and the MmpL3(G253) mutant in tandem and assayed them 
for compound binding. For this assay, we immobilized proteins on AR2G 
biosensors for use in biolayer interferometry (BLI). MmpL3(WT) yielded 
binding interactions with inhibitors IC4, IC21, and SQ109 under BLI 
conditions, which was in agreement with our SPR results for the same 
inhibitors (Figure 4.9A - Left). The G253E mutant exhibited an impaired 
binding interaction with IC4 inhibitor, and no measurable interaction with 
inhibitors IC21 and SQ109 (Figure 4.9A - Right). There were no 
measurable differences in binding with any of the other tested inhibitors, 
which indicated that the G253E substitution somehow selectively 
interferes with the inhibition interaction of MmpL3.     





Figure 4.9 – Biolayer Interferometry sensorgrams of inhibitor 
interaction with MmpL3(WT) and (G253E) resistant mutants.  
A) Inhibitor binding comparison of WT MmpL3 (Left) with resistant G253E 
mutant (Right). Compounds were tested at 50/100/200µM concentrations 
(black, blue and green lines) and were fit to a 1:1 binding model (red 
lines).  B) Normalized BLI response for inhibitors interacting with WT 
MmpL3, all inhibitors tested at 200µM with the exception of BM212 which 




4.2.5 – Conformational Change in MmpL3(G253E) 
Our data in Figure 4.9 showed that the G253E mutation either 
abolished or impaired interaction with several different inhibitors but did 
not reveal an obvious mechanism as to how. We had already observed 
(Figure 4.3 & Figure 4.4) that the maximal response for many of the 
inhibitors obtained from SPR was of a higher magnitude than could be 
explained by the mass of the inhibitor interacting with the protein alone. 
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The maximal response from SPR is directly proportional to the amount of 
immobilized protein (Ligand) and the mass ratio of analyte and 
ligand153,154. Therefore, in order to generate signals of the larger Rmax we 
observed, either many molecules of inhibitor would need to bind to each 
protein (Binding Valency >1), or more likely, upon inhibitor binding the 
protein undergoes a conformation change which in turn generates our 
higher Rmax we observed.  
To test our conformational change hypothesis, we performed a 
partial proteolysis of both MmpL3(WT) and MmpL3(G253E). In this assay, 
we exposed purified protein to an increasing concentration of trypsin in the 
presence or absence of excess inhibitor compounds (Figure 4.10). 
Resolving the proteolytic pattern through SDS-PAGE and silver-staining 
revealed a fragmentation pattern that was mostly similar for both WT and 
G253E, except that the G253E mutant accumulated additional bands at 90 
kDa and 75 kDa which were not present in the WT protein. This result 
strongly supported our hypothesis that the G253E mutation conveys 
resistance to MmpL3 inhibitors through an alternative stable conformation. 
We did not observe any effect due to the addition of excess inhibitor, 
however this could be explained by the fast on and off rates measured 
through both BLI and SPR. Conformational change due to inhibitor binding 
would be very short-lived, making it difficult to capture enough of the 
induced conformer to proteolytically digest in the limited experimental time 
window.  
65 | P a g e  
 
 
Figure 4.10 – Proteolytic Profiles of MmpL3 (WT) and (G253E).  
Present in the figure are the proteolytic profiles of WT MmpL3 and 
MmpL3(G253E) in the absence and presence of three inhibitors: IC4 (Top 
pair), SQ109 (Middle Pair), and AU1235 (Bottom Pair). Protein 
concentration was standardized to 100nM for all experiments, (-) indicates 
no inhibitor DMSO control, (+) indicates the incubation of excess inhibitor 
(200μM). After incubation a ten-fold trypsin gradient was added. Figures 
are 12% SDS-PAGE separations visualized by silver-stain. WT MmpL3 
accumulated 4 distinct proteolytic fragments: 78 kDa (1), 69 kDa (2), 65 
kDa (3), and 59 kDa (4). MmpL3(G253E) also produces bands 2-4, but 
importantly contains 90 kDa (5) and a 75 kDa (6) band strongly suggesting 
an alternative stable conformation of MmpL3 imparted by this mutation. 
Tryptic fragment molecular sizes were calculated in ImageJ. 
66 | P a g e  
 
Chapter 5 – Participating partners, an initial 
exploration of the MmpL3 Interactome. 
5.1 - Introduction 
 Bacterial cell division is an essential and highly regulated process 
155,156, which requires the duplication of the entire bacterial genome and its 
proper localization into each of the identical daughter cells. As the cells 
begin to divide, new membranes need to be properly synthesized and 
incorporated at the dividing septa. In the CMN family there is an absolute 
reliance on mycolic acids being properly incorporated to form the 
protective outer membrane157. We hypothesized that mycolic acid export 
and incorporation into the cell wall would proceed as a function of multiple 
interacting enzymes around MmpL3, forming an ‘MmpL3 Interactome’. To 
test this hypothesis, a way to identify potential protein interactions with 
MmpL3 was needed. The Mary Jackson group at Colorado State 
University used the bacterial adenylate cyclase two-hybrid (BACTH) 
system to identify protein-protein interactions, both in solution and with 
integral membrane proteins. This system takes advantage of the 
adenylate cyclase from Bordetella pertussis which consists of two 
fragments (T18 and T25) which do not function when spatially separated, 
however when fused to proteins which interact the close proximity induces 
the formation of cAMP. The presence of cAMP can then activate a β-
galactosidase reporter which allows for simple identification of interacting 
partners158-160. 
For this purpose, M. tuberculosis MmpL3 was fused at either the N-
terminal or C-terminus with either the T18 or T25 fragment, generating the 
MmpL3 ‘baits’. These bait were then screened against the Mtb Gateway 
Clone Set (BEI) for interaction with every open reading-frame in the Mtb 
genome, resulting in 19 hits showing interaction with MmpL3161. Of these 
identified hits, we selected proteins which covered diverse cellular 
functions to further purify and assess for direct interaction via SPR. 
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Among these proteins, CrgA interacts with FtsZ and is involved in 
mycobacterial cell division162 and LprC is an unessential lipoprotein of 
unknown function163. Rv0207c was identified initially as part of a heme-
acquisition gene cluster164 whose specific function is unknown, however 
Rv0207c was of interest as it is adjacent to MmpL3 on the Mtb genome. 
MviN is a lipid II flippase involved in peptidoglycan synthesis165, and AftD 
is an arabinosyltransferase involved in the polymerization of 
arabinogalactan166,167. Both MviN and AftD carry out essential roles in 
forming components of the CMN family cell wall core. Neither Pks13 nor 
Ag85 reported as a hit in the BACTH assay, yet they were still further 
pursued due to the essential roles they play in the formation of mycolic 
acids and their integration into the mycomembrane, respectively. 
This chapter reports the results of the recombinant expression and 
purification of CrgA, pks13, LprC, Rv0207c, and MviN from E. coli. The 
purified proteins along with the secreted Antigen 85 complex (purchased 
from BEI) and AftD (provided by Marcia group) were analyzed for the 
binding interactions with MmpL3 using SPR. As mycolic acid synthesis is 
a highly conserved process it logically follows that mycolic acid 
incorporation should also be an essential conserved process, and 
therefore our initial exploration of the MmpL3 interactome could be used to 
identify more potential therapeutic targets across the CMN family. 
 
5.2 – Results 
5.2.1 - Purification of suspected interacting partners 
 The proteins identified in Table 5.1 were chosen for individual 
purification based on the BACTH results for their eventual use in SPR 
binding experiments. While pks13 was not identified as a possible 
interactor in that assay, its essential role in the formation of mycolic acids 
made it of interest for interaction studies with MmpL3. 
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Protein MW (kDa) pI Function  
CrgA 11.4 11.83 Cell division organization 
pks13 186 4.83 Condensase of mycolic acid 
LprC 32.9 6.5 unknown  
Rv0207c 26.2 4.47 unknown 
MviN 143.5 7.5 Lipid II flippase 
 
Table 5.1 – Proteins purified for assessment of interaction with 
MmpL3.  
All were found to be membrane associated or integral membrane proteins. 
  
 Owing to the diverse physical properties of each of these targets, 
one singular strategy was not sufficient to accomplish the purification of all 
five proteins. Recombinant expression of targets was confirmed for all 
proteins in Escherichia coli; CrgA, Pks13, and Rv0207c were purified from 
E. coli Rosetta (BL21) harboring pET29a:crgA, pET26b:pks13, and 
pET29a:rv0207c respectively, while LprC and MviN were purified from E. 
coli BL21(C43) carrying plasmid pET14b:lprC and pET29a:mviN. 
Complete methods are detailed in Chapter Two. Briefly, membrane 
isolation and subsequent solubilization were carried out differentially, with 
LprC and Rv0207c requiring additional passage through a cation-
exchange resin prior to affinity purification. All protein constructs carry a C-
terminal 6x Histidine affinity tag, were loaded onto a copper charged His-
binding resin, washed, and eluted similarly with the purification results 
shown in Figure 5.1.  
 
 




Figure 5.1 - Purification of suspected MmpL3 interactors.  
A) 16% SDS-PAGE of the His affinity purified CrgA visualized by 
Coomassie blue. Lys: solubilized membrane fraction, FT: flow-through the 
His-bind column, W1-W4: 5CV 20mM imidazole wash fractions, Elutions 
(1-6) obtained with 400mM imidazole yielding 574 µg/ml. Purified protein 
indicated with Red asterisk. Indicated MW bands at 25 kDa and 70 kDa. 
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B) 8% SDS-PAGE of the His affinity purified Pks13 visualized by 
Coomassie blue. W4: Final 5CV 20mM imidazole wash fraction, Elutions 
(1-6) obtained with 400mM imidazole yielding 2.1 mg/ml Purified protein 
indicated with Red asterisk. Indicated MW bands at 25 kDa and 70 kDa. 
C) 16% SDS-PAGE of the His affinity purified LprC visualized by 
Coomassie blue. Elutions (1-3) obtained with 400mM imidazole yielding 
1.2 mg/ml. Purified protein indicated with Red asterisk. Indicated MW 
bands at 15 kDa and 25 kDa. D) 16% SDS-PAGE of the His affinity 
purified Rv0207c visualized by Coomassie blue. CEX FT: flow-through 
from SP Sepharose cation exchange column, HIS FT: flow-through from 
His-bind affinity column, W1-5: 5CV wash fractions containing 20mM 
imidazole, Elutions (1-6) obtained with 400mM imidazole yielding 665 
µg/ml. Purified protein indicated with Red asterisk. Indicated MW bands at 
15 kDa and 25 kDa. E) 12% SDS-PAGE of the His affinity purified MviN 
visualized by Coomassie blue. HIS FT: flow-through of His-bind affinity 
column, W1-2: 5CV wash fractions containing 20mM imidazole, Elutions 
(1-6) obtained with 400mM yielding 1.8 mg/ml. Purified protein indicated 
with Red asterisk. Indicated MW bands at 70kDa, 100 kDa, and 130 kDa. 
 
5.2.2 – Direct interaction of proteins with MmpL3 
 We next sought to assay binding of our purified proteins to MmpL3 
using SPR. In addition to our five purified proteins, we acquired AftD which 
was a positive hit identified during the BACTH screening, and the antigen 
85 complex. All proteins were either diluted, or centrifuge concentrated as 
appropriate, to achieve a 10 µM concentration and were then diluted 2-fold 
down to form a concentration series of injected analytes. No specific 
interaction with MmpL3 was detected for MviN, LprC, Pks13, or the Ag85 
complex (Figure 5.2A), revealing that the interaction suspected for LprC 
and MviN were false positives, and that Ag85 and pks13 were true 
negatives. Binding interactions were detected for AftD, Rv0207c, and 
CrgA (Figure 5.2B), with similar binding affinities for AftD and Rv0207c 
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(172 nM and 152 nM respectively) and a higher affinity interaction for 
CrgA (47 nM). The binding results for CrgA, Rv0207c, and AftD were in 
agreement with the BACTH association hits. The confirmed interactions 
with CrgA and AftD associate MmpL3 with cell-division and 
arabinogalactan synthesis, respectively; the confirmed interaction with 
Rv0207c is reasonable given their adjacent genetic location, however the 
functional significance of this interaction remains unclear and is the 




Figure 5.2 – Binding interactions of the suspected MmpL3 
Interactome. All proteins were concentrated to a top concentration of 
10µM and serial two-fold diluted down to 0.625µM for our injected 
concentration series. Proteins were injected at a 15 μl/min flow-rate and 
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were allowed to associate for 30 seconds, then dissassociation was 
measured for an additional 60 seconds. A) No binding interactions 
detected for MviN, LprC, Pks13, or the Ag85 Complex. B) Sensorgrams of 
binding partners AftD, Rv0207c, and CrgA (purple–blue–green lines, 
respectively) were globally fit to a 1:1 binding model (red lines). 
Sensorgrams for interacting proteins were global fit to a simple 1:1 binding 
model, and affinity constants were calculated in the mid to low nanomolar 
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Chapter 6 - Discussion  
The studies partaken in this work have demonstrated a functional 
overlap in the mycolic acid transporters of distant relatives within the CMN 
family, with evidence supporting the possibility of development of broad 
spectrum anti-CMN family drugs. As the mycolic acid synthesis and 
processing pathway is highly conserved in this family, targeting not only 
the synthesis of mycolic acids but also their essential transport out of the 
cell, will allow for a more effective and broader spectrum treatment. As C. 
glutamicum CmpL1 is a functional homolog of M. tuberculosis MmpL3, we 
gained mechanistic understanding in the interaction of these transporters 
with various novel inhibitors and substrates using a combined approach of 
surface plasmon resonance and biochemical reconstitution.  
The biochemical reconstitution of MmpL3 and CmpL1 into 
proteoliposomes provided the first insight into the mechanistic action of 
mycolic acid transport, confirming that the function is dependent upon H+ 
translocation. It was observed in the crystal structure published of 
MmpL3141 that there were molecules of a detergent bound in a 
hydrophobic pocket which could potentially function as an exit site during 
mycolic acid efflux/flipping. To begin exploring potential substrate binding 
activities of MmpL3, we attempted to mimic the native substrate Trehalose 
Mono-Mycolate (TMM) with compound AcTre67, which possesses a 
palmitic acid esterified to a trehalose head group. To test whether the 
length of the fatty tail was involved in substrate recognition, we assayed a 
series of analogous substrate mimics with shorter hydrophobic tails, and 
we observed a trend of improving CmpL1 substrate transport activity with 
the shorter tailed molecules. With MmpL3 the smaller substrate analogs 
all exhibit worse transport than the longer AcTre67 compound, which 
suggests that there is a preferred acyl tail length for the different 
transporters. However, recognition of substrate by mycolic acid 
transporters is likely based off a different mechanism than simply the size 
of the attached lipid, otherwise we would expect the smaller acyl tails to 
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function similarly to the longer substrates. While AcTre67 was chosen as 
a substrate analog for TMM due to the similar chemical structure to the 6-
DDTre detergent observed in the published crystallized structure of 
MmpL3 from M. smegmatis141, it is not an exact replacement as it is 
lacking the mycolic motif which is unique and formed in the natural 
substrate during the condensation of the alpha and mero-chain fatty acids, 
as well as the acetylation on this mycolic motif which seems essential for 
in vivo transport recognition104. Further mechanistic activity studies with 
substrates that more closely mimic this mycolic motif are needed. 
Novel indole-2-carboxamide (IC) compounds designed as MmpL3 
inhibitors and possessing potent anti-tubercular properties were shown to 
have selective activity against C. glutamicum strains dependent upon 
CmpL1 for viability. This result not only allows the early elimination of 
compounds that demonstrate activity in M. tuberculosis through off-target 
or non-specific effects, but also establishes a framework for the 
development of compounds which can selectively target members across 
the CMN family. We were able to demonstrate, via SPR, the effects of 
minor changes to chemical scaffolds which impede the interaction of 
compound with the targets, which suggests a discrete structural 
vulnerability in the homologous transporters. IC5, IC46, and IC52 all 
demonstrate good activity in vivo against M. tuberculosis with low M 
MIC’s and based only on this inhibitory activity, would indicate that IC52 is 
the least potent. However, based on the SPR binding data we collected, 
the modifications present on IC5 and IC46 seem to enhance an unknown 
off-target inhibitory effect. Finally, by comparing the M. tuberculosis 
MmpL3 activity data to C. glutamicum CmpL1, we can quickly eliminate 
the off target compounds and can isolate those that perform their activity 
solely through the inhibition of CmpL1, and by proxy, MmpL3. 
 The data reported in this dissertation have shown that mycolic acid 
transport inhibitors do directly interact with the transporters. It had been 
previously known that after inhibitor incubation, labeled mycolic acids build 
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up in the inner leaflet of the cytoplasmic membrane109. Through our 
published results126 we now understand that the inhibitors prevent H+ 
translocation necessary for lipid transport by directly interacting with the 
transporters and blocking the H+ antiport pathway. The reconstitution of 
these transporters themselves yielded some mechanistic insight into how 
the inhibitors preform their function, as early in the reconstitution process 
the lipid-detergent-protein mixture is diluted below the CMC of detergent 
which causes the protein to be stabilized in a lipid bilayer, and the bilayer 
itself forms into vesicle. Vesicle formation is a spontaneous process, and 
the eventual proteoliposomes can form in two opposite orientations: with 
the periplasmic protein loops extending either into or outside the vesicles. 
When this happens, we would expect a H+ antiport mechanism to 
demonstrate the ability to pump H+ into or out of vesicles depending on 
which direction the concentration gradient was directed, which is what we 
directly observed with MmpL3. At pH 6.0 we observe H+ flux into the 
vesicle which would describe the expected wildtype orientation of the 
protein with the periplasmic loops extending away from the vesicle, and 
when treated with inhibitors this transport is impaired with IC21, IC52, and 
IC4. However, at pH 8.0 we observe H+ flux out of the vesicle which 
describes the opposite orientation of the protein, and when treated with 
inhibitors in similar fashion revealed different activity patterns. IC21 and 
IC4 no longer inhibit transport in this orientation, while IC52 demonstrates 
an unchanged inhibitory activity. This result suggests that IC52 can 
access its binding site more readily from either side of the membrane; 
whereas there is a preferred MmpL3 orientation for binding access for 
both IC4 and IC21, specifically when the compounds are finding their 
target site when approaching the protein from the periplasmic face.  
A well-documented aspect of bacterial cell wall synthesis is the 
coordinated activity of multiple enzymes working in concert. As mycolic 
acids are such an essential building block of the mycobacterial cell wall, 
and these large hydrophobic lipids must traverse the periplasm to their site 
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of incorporation, we hypothesized that there must be other proteins 
interacting with MmpL3 for mycolic acid transport. A genome wide screen 
for interacting proteins revealed surprisingly few hits among the known 
enzymes involved in mycolic acid biosynthesis, instead yielding a few 
proteins involved in varying aspects of cell wall synthesis or lipid 
metabolism. We discovered a high affinity interaction with AftD, an 
essential integral membrane protein which functions as an 
arabinosyltransferase for the biogenesis of lipoarabinomannan and the 
arabinogalactan matrix. We also uncovered similarly high affinity 
interactions with CrgA, a small membrane protein involved in the 
recruitment or stability of the bacterial divisome, and Rv0207c which has 
no known function but is located immediately downstream to MmpL3 on 
the Mtb genome. We published our results on these protein-MmpL3 
interactions161, which will hopefully lead to more therapeutic targets 
located at the newly described interacting interfaces. 
Our studies also demonstrate a lack of interaction with the Antigen 
85 complex, which was surprising as we believed they could possibly 
function as mycolic acid acyl carriers, shuttling the mycolic acid from the 
outer leaflet of the inner membrane to its destination before catalytically 
transferring it to either arabinogalactan or converting it to TDM. A plausible 
explanation for how TMM gets to its periplasmic destination would be that 
TMM excretion is carried out predominately at the septa of dividing cells, 
where membrane is being synthesized de novo, and would explain why 
MmpL3 localizes to these positions in the membrane126.  
Despite the recent advances in understanding how mycolic acids 
are produced and transported in mycobacteria, there remain several 
unanswered questions. Whether MmpL3 functions as a homotrimer akin to 
an RND efflux pump of Gram-negative bacteria is an active pursuit of our 
research group, or if it truly carries out its activity as a monomeric lipid 
flippase. Another unanswered question is how MmpL3 can recognize its 
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substrate given the large saturated hydrophobic nature of TMM; why an 
acetylation signal on the TMM is necessary for export, and at what stage 
the acetyl group is removed from the mature TMM, as perhaps there are 
still unknown essential enzymes in the emerging MmpL3 interactome. 
Since the viability of mycobacteria largely depends on the proper spacio-
temporal biogenesis of the myco-membrane, answering these outstanding 
questions could reveal more pharmaceutically relevant therapeutic targets 
and improve the prognosis of tuberculosis diagnosis in the face of 
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